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1.1 BACKGROUND 
The word “Chemotherapy” was developed after the observation that the soldiers from World 
War I and II exposed to nitrogen compounds showed decrease in the levels of leukocytes [1-
2]. Therefore, the use of alkylating drugs (cyclophosphamide, chlorambucil and cisplatin) 
was increased to treat lymphomas [3-4]. Chemotherapy is commonly used as a treatment of 
cancers with or without surgical [5-8] and radiation therapy [9-12]. Furthermore, one of the 
major reasons for unsuccessful chemotherapy is the limited accessibility of drugs to the 
tumor, needing higher doses. The higher doses of chemotherapeutic agents result in 
generalized toxicity and thus decrease the quality of life. Another problem to face in the arena 
of chemotherapy is the development of resistance against anti-neoplastic agents due to their 
non-specific delivery. Therefore, the focus of treatment is changing towards other advance 
options e.g. targeted therapy and immunotherapy [13-14].  
1.2 TARGETED CHEMOTHERAPY 
The efforts to combat problems regarding the non-selective chemotherapy have led to 
targeted drug delivery [15-18]. The development of targeted drug delivery systems has 
resulted in the effective therapeutic outcomes [19-20]. Microparticles, nanoparticles and 
liposomes are the pharmaceutical dosage form getting importance in targeting cancers. The 
targeting of the cancerous cells is possible due to unique small sizes of these formulations 
[21-23]. Targeting may be achieved either by passive or active targeting. 
1.2.1 Passive Targeting 
Passive targeting is usually achieved by controlling the sizes, morphology, surface charge and 
stealthing of the formulations used to deliver chemotherapeutic agent. Tumor tissues, due to 
rapid growth, are rich in blood vessels and endothelial junctions are loose. Typically, the pore 
size in normal vessel is 5-10 nm while in case of tumor vessel; this size ranges from 200 nm 
to several hundred nanometer [24, 25]. This increased pore size is due to multiple factors e.g. 
increased blood circulation, inflammation, hypoxia etc. Therefore, the formulations of this 
size range can easily leak through these junctions and exert their pharmacological effects 
(Figure 1.1). This phenomenon is known as enhanced permeation and retention (EPR) [25-
26]. However, particles more or less than this pore size nm are usually not cleared by renal 
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clearance. Therefore, they may end up in the form of reticuloendothelial system (RES) 
retention [27-28]. Therefore, there is a need to modify the surfaces of these formulations so 
that they can bypass RES and show their effects in tumor cells. 
1.2.2 Active Targeting 
Nano-scale formulations can be modified by different ligands (e.g. aptamer, antibodies, 
siRNA, peptides etc.) to by-pass the RES [29-30]. These modifying ligands are targeting 
agents against tumor surfaces, DNA or other molecule. Therefore, surface modified 
nanoparticles or liposomes will bind to targeted cells (Figure 1.1) and will be then 
internalized by clathrin-mediated endocytosis, caveolae-mediated endocytosis, combined 
endocytotic pathways or clathrin/caveolae independent internalization pathways [27-28, 31-
32]. These internalized particles, release their content inside cells which inhibit cellular 
proliferation and metastasis by intracellular supply of particles to specific targets. Beside 
these, small molecule drug inhibitors (e.g. Sorafenib and Imatinib) are also used to inhibit 
specific activity in cancers. These are small enough that can be easily absorbed by body as 
compared to antibodies. They are also non-immunogenic because are chemically synthesized 
[29, 33]. Thus active targeting therapies have more advantages over passive therapies due to 
specific delivery of drug to tumor tissues only. The active drug delivery systems by pass RES 
and thus accumulate in tumor tissues due to EPR. Therefore, the decreased generalized body 
drug distribution results in less side effects and overall quality of life of the patient is 
improved. 
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Figure 1.1: Passive and active targeting of cancer tissues [24, 27]. 
1.3 ADVANCE COLLOIDAL SYSTEMS FOR TARGETED 
CHEMOTHERAPY 
1.3.1 Polymeric Matrices 
Nanoparticles are small entities with size ranges from few nano-meters to a few hundreds of 
nano-meters [34]. On the other hand, microparticles size ranges from a few hundred nano-
meters to several micro-meters. Nanoparticles and microparticles are solid matrices of 
polymers or mixture of polymers which may contain drug or other molecules of interest. The 
drug molecules can either be entrapped inside or adsorbed on the surfaces of these 
formulations [35-37]. Their size makes them good candidate for passive drug delivery to 
cancer cells and make them reside in tissue spaces due to EPR [38]. However, their surfaces 
can be modified to make them good candidates for active targeting. The surface modification 







Immune Cell Targeting Moiety 
Passive Targeting Active Targeting 
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1.3.1.1 Methods of Preparation 
The preparation of nanoparticles/microparticles is two step processes. The first step usually is 
the formation of emulsion and the second step ends up in the formation of 
nanoparticles/microparticles. The methods of preparation mostly depend upon the starting 
polymers. A variety of polymers is used for the preparation of these formulations. The most 
commonly used polymers can be classified as follows [35, 39-41]; 
 
Table 1.1: Classification of most commonly used polymers for nanoparticles/microparticles. 
Sr. No. Class Polymer Abbreviation 





















4.  Colloidal 
Stabilizers 
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1.3.1.1.1 Spray Drying 
Spray drying is the procedure of conversion of polymeric solution into dried particles, when 
liquid or dispersion is atomized in the form of spray and subjected to drying. The typical 
spray drying process encompasses three fundamental steps. The first step involves the 
atomization of feed. Liquid feed can be sprayed either by solution or by colloidal form. 
Second step of preparation involves the drying of spray with the help of stream of warm 
drying gas. The last step of preparation is separation and collection of dried product from the 
drying air [42]. Inlet temperature, drying gas heat flow and feed rates are the main process 
controls of the procedure. This technique is mostly used for the preparation of particles 
intended for pulmonary, nasal and control release oral delivery.  
1.3.1.1.2 Solvent Evaporation 
Solvent evaporation techniques are performed by agitation of two immiscible liquids (o/w or 
w/o emulsion). The first step requires emulsification of one liquid phase into another liquid phase. 
Homogenization is done to get controlled size droplets. During the second step, dispersed phase 
solvent is evaporated with the help of continuous stirring and thus results in core solvent 
evaporation forming nanoparticles/microparticles [43]. Finally, washing is done by 
centrifugation to remove the un-reacted surfactant. The process variables affecting the size 
are nature of solvents, the type of polymer, concentration of polymers, homogenization speed 
and rate of evaporation. 
1.3.1.1.3 Salting out Method 
In this method, polymer is dissolved in organic phase which is miscible with water. One 
example of such organic solvent is acetone. The aqueous phase consists of surfactant and 
electrolyte. The most commonly used electrolyte is magnesium chloride hexahydrate. The 
organic phase is uniformly distributed in the aqueous phase with/without the help of 
mechanical stirring. The water miscible organic solvent then migrates to aqueous phase 
changing the amount of organic solvent available for polymer. This results in the formation 
of precipitates in the form of nanoparticles/microparticles [44]. Finally, washing is done to 
separate the electrolyte, by centrifugation. The manufacturing parameters are 
internal/external phase ratio, stirring rate, concentration of polymers and electrolyte [45]. The 
greatest disadvantage of this method is extensive washing steps.  
INTRODUCTION 
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1.3.1.1.4 Nano-precipitation Method 
This method is mostly suitable for hydrophobic drugs. The polymers along with drug are 
dissolved in organic phase (may be acetone or methanol). This organic phase is drop-wise 
added to aqueous phase containing surfactant. The diffusion of solvents results in the 
fabrication of nanoparticles/microparticles [46]. The organic phase then can be evaporated 
under vacuum conditions. The key parameters in procedure are organic phase injection rate, 
organic to water phase ratio and aqueous phase agitation rate [47].  
1.3.2 Liposomes 
Liposomes are artificially prepared lipid bilayer vesicles of size range from nanometers to 
several micrometers [47]. They can be classified on the bases of number of lipid layers, their 
size and nature of phospholipids. On the basis of number of bilayers and size, liposomes can 
be divided into two categories i.e. multilamellar vesicles (MLV) and unilamellar vesicles. 
Unilamellar vesicles can further be classified into two types i.e. large unilamellar vesicles 
(LUV) and small unilamellar vesicles (SUV). On the other hand, on the bases of nature of 
phospholipids there can be either positively charged liposomes (cationic liposomes), 
negatively charged liposomes (anionic liposomes) or liposomes having no net charge (neutral 
liposomes). Both hydrophilic drug and hydrophobic drug can be entrapped in liposomes. 
Moreover, their surfaces can be modified by various strategies to make them suitable for 
targeted drug delivery and enhanced cellular internalization [48-49]. 
1.3.2.1 Methods of Preparation 
A range of different kinds of lipids are used for the preparation of liposomes. The selection of 
these lipids usually depends on the size, charge and methods of modification used for active 
targeting. They are modified with a polyethylene glycol group (PEG) which inhibits the 
liposomal uptake by RES and therefore result in a longer circulation time. Some of them the 
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Table 1.2: Examples of some commonly used lipids for liposomes. 
Sr. No. Name Abbreviation 
1.  1,2-dipalmitoyl-sn-glycero-3-phosphocholine DPPC 
2.  1,2-distearoyl-sn-glycero-3-phosphocholine DSPC 















[maleimide(polyethylene glycol)-5000]  
DSPE-PEG(5000) 
Maleimide 





10.  1,2-dioleoyl-sn-glycero-3-phosphoethanolamine DOPE 
11.  
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-








The preparation of liposomes needs to solubilize all the lipids in the organic phase. This 
organic phase is then either converted to dry lipid layer which is then hydrated or may 
directly be incorporated in the aqueous phase. These steps usually end up in the formation of 
MLV. The formed MLV are then sonicated or extruded from French pressure extruder to get 
SUV [50].  
1.3.2.1.1 Film Hydration Method 
The combination of lipids is dissolved in some organic solvent (usually mixture of 
chloroform and methanol). This step ensures the formation of homogenous lipids mixture. 
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The organic solvent is evaporated by heating and under vacuum to form uniform layer on 
some solid surface, usually a round bottom flask. The hydration of this layer results in the 
formation of MLV [49-50]. The temperature of hydrating medium (water or buffer) should be 
above phase transition temperature for effective hydration of lipid layer. 
1.3.2.1.2 Solvent Spherule Method 
The organic and water phases are mixed for nearly one hour under reduced pressure. The 
outcome of mixing is in the form of o/w emulsion. Thus the formed emulsion is subjected to 
the removal of organic phase to obtain MLV [49-50]. 
1.3.2.1.3 Reverse Phase Evaporation Method 
This method resembles with the solvent spherule method. However, the vigorous shaking 
results in the formation of w/o emulsion. The resultant emulsion, when subjected to organic 
phase evaporation, produces aqueous phase containing distributed large unilamellar vesicles 
[49, 51]. 
1.3.2.1.4 Solvent Injection Method 
This method is used to prepare SUV. The lipid components of liposomes are dissolved in 
ethanol. The organic phase is then injected in the aqueous phase, resulting in the fabrication 
of the formulation. The miscibility of ethanol with water results in decreased concentration of 
ethanol. Hence, the dissolved phospholipids assemble themselves in the form of SUV. In 
contrast, the injection of ether dissolved phospholipids cause liposome preparation after 
evaporation of ether [52-53].   
1.3.3 Characterization of formulations for targeted cancer therapies 
A number of different formulation related parameters influences efficiency of targeted 
therapies. These may include size, size distribution, zeta potential and morphological 
characteristics. Therefore, it is always the first and the most important topic of discussion to 
characterize these formulations. There is a list of variants for characterization; the most 
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Table 1.3: Techniques for characterization of colloidal used for targeted chemotherapies. 
Sr. 
No. 
Technique Application References 
1. 
Atomic Force Microscopy 
(AFM) 
Size and size distribution, shape, 




Brunauer, Emmett and 
Teller (BET) 
Surface area, porosity [56] 
3. 
Dynamic Light Scattering 
(DLS)  






Structure and stability [58-59] 
5. Elemental Analysis Elemental composition [56] 
6. 
Fourier Transform Infrared 
Spectroscopy (FTIR) 
Conformation and structure of 
conjugate, Surface properties  
[55, 58] 
7. 
Laser Doppler Velocimetry 
(LDV) 








Shape, size, size distribution [55, 61] 




Surface chemistry [61-62] 
12. X-ray Diffraction (XRD) 
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1.4 APTAMER 
Aptamers are small and single stranded DNA or RNA with highly selective targeting ability. 
In nature they exist in combination with mRNA, influencing protein production. They can 
bind with different molecules, peptides, proteins or viral particles by hydrogen bonding, 
electrostatic interactions, and van der Waals forces. They are far superior to antibodies as 
they are chemically synthesized and molecular weight is between 6 kDa to 30 kDa. They are 
more stable, have long shelf life, possess less batch to batch variations, have no or low 
immunogenicity and can be modified at both 5’ and 3’ ends with any required modification 
[63-65]. 
A range of different aptamers have been generated and approved by food and drug 
administration (FDA). These targets are involved in cell growth, proliferation, migration and 
metastasis during cancer growth. Therefore, blocking the activities of these targets will block 
the growth of cancer cells [66-71]. A few examples of aptamers with target molecules are 











Figure 1.2: Some examples of aptamers (shown in black boxes), their targets and functions 


















ErbB: Avian Erythroblastosis Oncogene B PSMA: Prostate Specific Membrane Antigen 
VEGFR: Vascular Endothelial Growth Factor Receptor 
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1.5 AIM AND SCOPE 
The high expression of different cell surface receptors in cancerous cells as compared to 
normal cells is well known fact now a days. ErbB3 is one of the receptor tyrosine kinase 
(RTK) and it is present in much higher concentration in cancerous cells. This receptor is 
responsible for cell growth, proliferation and metastatic progression [72-77]. Therefore, 
inhibition of this receptor by a ligand can arrest cell signaling and ultimately the growth of 
tumors [78-83]. Thus, surface modification of drug-loaded colloidal systems with an anti-
ErbB3 aptamer, to achieve specific drug delivery, was the main objective of current study.  
Sorafenib was used as chemotherapeutic agent in all advance colloidal systems 
(nanoparticles, microparticles and liposomes). A set of different in vitro and in vivo 
experiments were performed to validate the idea of combining this chemotherapeutic agent 
and aptamer. Briefly, the key aspects of the study are as follows; 
1. Designing of advance colloidal systems (nanoparticles, microparticles and liposomes) 
2. Optimizing the formulations according to physiochemical properties 
3. Surface modification with anti-ErbB3 aptamer (Figure 1.3) 
4. Physico-chemical characterization of final formulations before and after surface 
modification 
5. Confirmation of cytotoxicity and apoptosis body formation by formulations with and 
without drug and/aptamer 
6. Assessing the internalization method of formulations by clathrin and caveolae-mediated 
endocytosis 






Page | 13 
 
 
Figure 1.3: Schematic representation of preparation, surface modification, internalization and 
degradation of PLGA particles. 
 
1. Organic phase 
2. Aqueous phase 
3. Homogenization 








      degradation 
11. Cell growth  
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2.1 MATERIALS 
2.1.1 Chemicals, Reagents, Equipments and Software 
Table 2.1: List of chemicals. 
Name Company 
1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide Sigma Aldrich, Darmstadt, Germany 
1,2-dipalmitoyl-sn-glycero-3-phosphocholine Lipoid GmbH, Ludwigshafen, Germany 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[cyanur(polyethylene glycol)-2000] 
Avanti Polar Lipids, Alabam, USA 
2-(N-morpholino) ethanesulfonic acid  Serva, Heidelberg, Germany 
2′,7′-dichlorofluorescein diacetate  Sigma Aldrich, Darmstadt, Germany 
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H- 
tetrazolium bromide 
Sigma Aldrich, Darmstadt, Germany 
4′,6-diamidino-2-phenylindole  Sigma Aldrich, Darmstadt, Germany 
Agar Sigma Aldrich, Darmstadt, Germany 
Agarose Carl Roth, Karlsruhe, Germany 
Calcium Chloride Carl Roth, Karlsruhe, Germany 
Chloroform Sigma Aldrich, Darmstadt, Germany 
Cholesterol Sigma Aldrich, Darmstadt, Germany 
Disodium Hydrogen Phosphate  Carl Roth, Karlsruhe, Germany 
Dimethyl Sulfoxide  Acros Organics, Geel, Belgium 
Ethanol Fisher, UK 
Ethyl Acetate Chemsolute, TH. Geyer, Germany 
Magnesium Chloride Carl Roth, Karlsruhe, Germany 
Methanol Sigma Aldrich, Darmstadt, Germany 
N-Hydroxysuccinimide  Sigma Aldrich, Darmstadt, Germany 
Paraformaldehyde Carl Roth, Karlsruhe, Germany 
Poly(lactic-co-glycolic acid) Evonic Darmstadt, Germany 
Poly Vinyl Alcohol  Kuraray, Hattersheim, Germany 
Potassium Chloride Merck, Darmstadt, Germany 
Potassium Dihydrogen Phosphate Merck, Darmstadt, Germany 
Purified Water Purelab Flex, Elga, UK 
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Sodium Chloride Carl Roth, Karlsruhe, Germany 
Sorafenib Tosylate LC Laboratories, USA 
Tert-Butylhydroperoxide Sigma Aldrich, Darmstadt, Germany 
Tetrahydrofuran Carl Roth, Karlsruhe, Germany 
Tris (hydroxymethyl) amino methane Merck, Darmstadt, Germany 
Triton™ X-100 Sigma Aldrich, Darmstadt, Germany 
 
 
Table 2.2: List of cell culture medium and reagents. 
Name Company 
Anti-ErbB3 aptamer Eurogentec, Belgium 
Dulbecco's Modified Eagle Medium Capricorn Scientific, Ebsdorfergrund, Germany 
FluorSave Calbiochem Corp, La Jolla, USA 
Foetal Bovine Serum Capricorn Scientific, Ebsdorfergrund, Germany 
Iscove's Modified Dulbecco's Media  Capricorn Scientific, Ebsdorfergrund, Germany 
MDA-MB-231 Cell Line ATCC, Manassas, USA 
Roswell Park Memorial Institute Medium  Capricorn Scientific, Ebsdorfergrund, Germany 
SK-OV-3 Cell Line ATCC, Manassas, USA 
Trypsin –EDTA Sigma-Aldrich, St. Louis, USA 
 
 
Table 2.3: List of equipments. 
Name Company 
AFM Probe; HQ:MSC16/Al BS  Micromasch, Tallinn, Estonia 
Atomic Force Microscope; Nanowizard® 1  JPK Instruments AG, Berlin, Germany 
Autoclave; DX-45 Systec lab, Linden, Germany 
Bath Sonicator; Transonic Digital S  Elma Schmidbauer GmbH, Singen, Germany 
Bioshaker; KS4000 IC  IKA Werke, Staufen, Germany 
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Carbon Tabs  PLANO GmbH, Wetzlar, Germany 
CCD-Camera; Gatan Mega Scan 794  Gatan Inc., Pleasanton, USA 
Cell Culture Lysis Reagent  Promega GmbH, Mannheim, Germany 
Centrifuge; Eppendorf 5418 Eppendorf, Hamburg, Germany 
Centrifuge; Beckman J2-21  Beckman Coulter GmbH, Krefeld, Germany 
Confocal Laser Scanning Microscope LSM 
700 
Carl Zeiss Microscopy GmbH, Jena, Germany 
Digital Image Acquisition System; DISS 5 Point Electronic GmbH, Halle, Germany 
Extruder; Avanti Mini  Avanti Polar Lipids Inc., Alabaster, USA 
Fluorescence Microscope; CKX53 Olympus, Hamburg, Germany 
Fluostar Optima Plate Reader  BMG Labtech, Offenburg, Deutschland 
Freeze Drier; Christ Beta I  
Martin Christ Gefriertrocknungsanlagen 
GmbH, Osterode am Harz, Germany 
Laminar Flow Hood; Labgard Class II  NuAire Inc., Plymouth, USA 
Magnetic Bar  IKA-Werke, Staufen, Germany 
Microscopy Slides  
Gerhard Menzel B.V. & Co. KG., 
Braunschweig, Germany 
Multichannel Pipette  Mettler Toledo, Gießen, Deutschland 
Multistage Magnetic Stirrer RT10 Power IKA-Werke, Staufen, Germany 
Pipette Tip 100-1000 µl  Sarstedt, Nümbrecht, Germany 
Pipette Tip 10-200 µl  Sarstedt, Nümbrecht, Germany 
Pipette Tip 1-10 µl  Sarstedt, Nümbrecht, Germany 
Rotary Evaporator; Laborota 4000 
Heidolph Instruments GmbH & Co. KG., 
Schwabach, Germany 
Scanning Electron Microscope; Hitachi S-
510  
Hitachi-High Technologies Europe GmbH, 
Krefeld, Germany 
Spectrophotometer; Ultrospec 3000 Pharmacia Biotech AG, Uppsala, Sweden 
Sputter Coater; Edwards S150  Edwards, Crawley, UK 
Thermometer  IKA-Werke, Staufen, Germany 
Ultrasound Bath; Elma Elmasonic P 
BANDELIN electronic GmbH & Co. Berlin, 
Germany 
UV Spectrophotometer; UV mini 1240 Shimadzu, Japan 
Vacuum Pump; SC 920  KNF Neuberger GmbH, Freiburg, Germany 
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Water Bath  
Kottermann GmbH & Co. KG.,  Hänigsen, 
Germany 
Weighing Balance; ExplorerEX225D  Ohaus, Parsippany, USA 
Zetasizer Nano ZS  Malvern Instruments Ltd, Malvern, UK 
 
Table 2.4: List of self prepared buffers and reagents. 
Name Ingredients Quantity 
Anti-ErbB3 Aptamer Anti-ErbB3 Aptamer 













Purified Water (QS) 
9.76 g 
2.92 g 
500 ml  
MTT Reagent  
(0.2 %) 
MTT 





















Phosphate Buffer  
















Poly Vinyl Alcohol 
 
PVA 
Purified Water (QS) 
2.00 g 
100 ml 
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TAE Buffer Tris HCl 
Glacial Acetic Acid 
EDTA (pH 8.0) 





Tris Buffer  
(0.1 % v/v) 
Triton X-100 




Table 2.5: List of consumables. 
Consumable Company 
0.2 μm PES Syringe Filters Whatman PLC, Buckinghamshire, UK 
1.5 ml Microtubes Sarstedt, Nümbrecht, Germany 
12-well plates; Nunclon Delta Nunc GmbH & Co. KG., Wiesbaden, Germany 
15 ml Falcon Tubes  Sarstedt, Nümbrecht, Germany 
18×18 mm cover slips  
 
Gerhard Menzel B.V. & Co. KG., 
Braunschweig, Germany 
24-well plates; Nunclon Delta  
 
Nunc GmbH & Co. KG., Wiesbaden, Germany 
3.5 ml Transfer Pipette  Sarstedt, Nümbrecht, Germany 
50 ml Falcon Tubes Sarstedt, Nümbrecht, Germany 
96-well plates White  Brand, Wertheim, Germany 
96-well plates; Nunclon Delta  Nunc GmbH & Co. KG., Wiesbaden, Germany 
Adhesive plate seals  
Boehringer Mannheim GmbH, Mannheim, 
Germany 
Disposal Bags  Sarstedt, Nümbrecht, Germany 
Paraffin film M  Bemis, Braine L’ Alleud, Belgium 
Petri Dishes; Tissue Culture grade Sarstedt, Nümbrecht, Germany 
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Table 2.6: List of software. 
Software Version 
ChemDraw Version 7 
Gimp Version 2.10.6 
GraphPad Prism  Version 8.0.1 
ImageJ 152 Win 
Minitab Version 17  
Microsoft Office MS 2007 
Origin 2016 
SketchAnd CalcTM Free Windows Tool 
 
2.1.2 Polymers and Lipids 
2.1.2.1 PLGA 
Poly (lactic-co-glycolic acid) abbreviated as PLGA is white amorphous powder and is 
amongst one of the FDA approved polymer for pharmaceuticals. PLGA 503H (50:50, 
Lactide:Glycolide) was used for the preparation of nanoparticles and microparticles (Figure 
2.1). Its molecular weight is 30,000 g/mol and stored between 2-8 °C. This polymer contains 
–COOH group at end terminal and thus is suitable candidate for any carboxylic acid reaction 
[84-85]. PLGA used in current study was obtained from Evonic Darmstadt, Germany. For the 











x y  
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2.1.2.2 PVA 
Polyvinyl alcohol abbreviated as PVA is an odorless and white to cream-colored granular 
powder. Its molecular weight is ~31,000 g/mol [84]. It is one the most commonly used 
stabilizer and viscosity-increasing agent in pharmaceuticals [86]. 2 % stock solution was 
prepared by heating 2 g of PVA in 100 ml purified water (Purelab Flex, Elga, UK) at 60 oC 
with constant stirring. The final solution was filtered through 200 nm PES syringe filters 
Whatman PLC, Buckinghamshire, UK. The stock solution was then stored between 2-8 °C 






Figure 2.2: Structural formula of PVA. 
2.1.2.3 DPPC 
Dipalmitoylphosphatidylcholine (1,2-dipalmitoyl-sn-glycero-3-phosphocholine), abbreviated 
as DPPC is white amorphous powder and is one of the most commonly used fatty acid 
derivative used in liposomal preparation. Its molecular weight is 734.04 g/mol and phase 
transition temperature is 41 oC [84]. It is rarely used as auxiliary agent in liposome 
preparation because of less stability [87]. Hence cholesterol is commonly used along with 
DPPC to increase stability of liposomes. Cell membrane lipid bilayer is rich in DPPC. 
However, DPPC used during current study was of chemical origin. 10 mg of this lipid was 
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Figure 2.3: Structural formula of DPPC. 
2.1.2.4 DSPE-PEG(2000) Cyanur 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[cyanur(polyethylene.glycol)-2000] is 
white to off-white amorphous powder and has molecular weight 2938.44 g/mol (Figure 2.4). 
This lipid is used for post formulation modification of liposomes. Primary amine linked 
antibodies or aptamer can be attached on the surface of liposomes in the presence of this lipid 
[88]. 10 mg of this lipid was dissolved in 1 ml chloroform:methanol (2:1) and stored at -20 oC 







Figure 2.4: Structural formula of DSPE-PEG (2000) cyanur. 
2.1.2.5 Cholesterol 
Cholest-5-en-3b-ol is white to faintly yellow and almost odorless powder or granule (Figure 
2.5). Its molecular weight is 386.67 g/mol [84]. It may be used up to maximum 50 mol % 
[89] and imparts stability to the liposomes. The stability is due to decrease surface interaction 
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change in phase transition temperature [90]. 10 mg of cholesterol was dissolved in 1 ml 





Figure 2.5: Structural formula of cholesterol. 
2.1.3 Sorafenib Tosylate 
Sorafenib tosylate (SFB) is white crystalline to powder solid with molecular weight 637.03 
g/mol (Figure 2.6). Its LogP value is 4.54 with biopharmaceutical classification systems 
(BCS) class IV making it poorly soluble in water but freely soluble in DMSO [91]. SFB is 
oral multi-kinase inhibitor, inhibiting VEGFR (vascular endothelial growth factor receptor) 
and PDGFR (platelet derived growth factor receptor), resulting in inhibition of angiogenesis 








Figure 2.6: Structural formula of sorafenib tosylate. 
 
2.1.9.1 Anti-ErbB3-Aptamer 
Anti-ErbB3 RNA aptamer, (Apt) with 5’ cyanine 5 (Cyn 5) and 3' C6 amino modifier spacer 
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chemotherapy. Fluorescent dye was intentionally attached to Apt to visualize formulations in 
cell culture studies. The primary amine of C6 spacer group (Figure 2.7) also provided space 
for attachment of aptamer on the surfaces of formulations. 3’ end modification was done to 
save aptamer from attack of nucleases [94-95].  The mother solution of Apt was prepared in 




Figure 2.7: 3' C6 Amino modifier group. 
2.1.10 Cell Line and Cell Culture 
ErbB3 positive human breast cancer cell line MDA-MB-231 was purchased from ATCC 
Manassas, USA. Cells were grown in RPMI:DMEM (50:50) (Capricorn Scientific, 
Ebsdorfergrund, Germany) supplemented with 10 % fetal bovine serum (Sigma Aldrich). 
Cells were cultivated in humid conditions at 37 °C and 7% CO2.  
2.2 METHODS 
2.2.1 Preparation of Formulations 
2.2.1.1 Preparation of Nanoparticles and Microparticles 
Preparation of PLGA nanoparticles (PN) was performed by o/w emulsion solvent evaporation 
method [43]. Briefly, 50 mg of PLGA was dissolved in 5 ml of ethyl acetate (organic phase). 
The organic phase was added drop wise to a 5 ml solution of 2 % of PVA in purified water 
(Purelab Flex 4, Elga Labwater, High Wycombe, UK). The resultant emulsion was then 
homogenized using Ultra-turrax homogenizer (IKA-T25, IKA Werke, Staufen, Germany) 
with 18 G dispersing stainless steel element at a constant speed of 14,500 rcf for 10 min. 
Water was added to facilitate organic solvent evaporation (see Graphical Abstract). SFB-
loaded PLGA nanoparticles (PNS) were prepared by the same method, except that SFB was 
dissolved in THF:EtOH (4:1) and was mixed with PLGA solution in ethyl acetate. On the 
other hand, the preparation of microparticles (MP)/ SFB-loaded microparticles (MPS) was 
also done with the same procedure except using 0.25 % solution of PVA and homogenization 
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three times with purified water followed by centrifugation for 10 min for each washing step. 
Finally, particles were re-suspended in purified water. 
 
Figure 2.8: Preparation of nano/microparticles and in vitro and in vivo characterization. 
 
2.2.1.2 Preparation of Liposomes 
Liposomes (LP) were prepared by film hydration method. Briefly, DPPC:Cholesterol:DSPE-
PEG (2000) cyanur (80:10:10) stock solutions were taken in 5 ml round bottom flask. Using 
rotary evaporator (Laborota 4000, Heidolph Instruments GmbH & Co. KG., Schwabach, 
Germany) equipped with vacuum pump, organic solvents were removed. This resulted in the 
formation of dried lipid layer. The film was hydrated with 1 ml of 100 mM sodium borate 
buffer (pH 8.8) making final concentration of lipids 5 mg/ml and sonicated in bath sonicator 
(Transonic Digital S, Elma Schmidbauer GmbH, Singen, Germany) for 20 min. The colloidal 
system of liposomes was then extruded 25 times through 200 nm polycarbonate membrane 
filters at 45 °C (Whatman, Buckinghamshire, UK) using an extruder (Avanti Mini, Avanti 
Polar Lipids Inc., Alabaster, USA). SFB-loaded liposomes (LPS) were prepared in similar 
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Figure 2.9: Preparation of liposomes by film hydration method. 
 
2.2.2 Encapsulation Efficiencies 
PNS and MPS were centrifuged (Eppendorf centrifuge 5418, Eppendorf, Germany) at 14,500 
and 10,000 rcf, respectively, for 10 min at room temperature. On the other hand, LPS were 
centrifuged at 6,000 rcf for 1 h at 4 °C. The supernatant was removed and the pellet was 
dissolved in DMSO to extract the drug from the respective formulations. Samples were 
analyzed by UV spectrophotometry (UV mini 1240, Shimadzu, Japan) at 265 nm. A 
calibration curve was recorded with known concentrations of the drug. The solvent 
background was recorded from particles without drug and encapsulation efficiency was 
calculated using the following equation: 
𝐸𝐸(%) =  
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2.2.3 In Vitro Release Profile 
The release profile of SFB was evaluated in PBS (pH 7.4) with 1 % v/v Tween 80. 1 ml of 
nano/microparticle suspension was washed thrice with PBS, followed by centrifugation at 
14,500 or 10,000 rcf, respectively, for 10 min. The pellets were re-suspended in 1 ml PBS 
with 1 v/v % Tween 80 and placed in an orbital shaker, KS4000 IC (IKA Werke, Staufen, 
Germany) at 150 rpm and 37 ± 0.5 °C. The samples were removed after designated time 
intervals, after centrifugation, the pellets were re-suspended in 1 ml PBS/1 % Tween 80 and 
returned to the shaker. After defined time intervals, pellets were dissolved in  
1 ml DMSO and analyzed by UV spectrophotometer (UV mini 1240, Shimadzu, Japan) at 
265 nm. The vehicle background was then subtracted by measuring the pellet of PLGA 
nano/microparticles, without SFB, prepared under the same condition. 
2.2.4 Surface Modification 
Surface modification of nano/microparticles was carried out using EDC and NHS coupling 
reaction with a primary amine at the 3’prime end of Apt. Particles were washed three times 
with purified water followed by centrifugation and finally re-suspended in MES buffer (pH 
5.5). They were then treated with 400 mM EDC and 200 mM NHS for 30 min for surface 
activation. The particles were incubated with Apt at a particle:Apt ratio of 1:12. This resulted 
in the reaction of the primary amine of Apt with EDC/NHS activated nano/microparticles. 
After 2 h of incubation, washing was done with purified water and nano/microparticles were 
re-suspended in purified water (Figure 2.10). The modified particles were stored at 4 °C until 
further use. 
On the other hand, for the modification of liposomes, Apt was added to prepared liposomes at 
equimolar DSPE-PEG (2000) cyanur: Apt ratios [88]. The reaction mixture was allowed to 
react for 24 h (Figure 2.11). The un-conjugated Apt was separated by dialysis (MWCO 6000) 
in PBS (pH 7.4). The modified liposomes were stored at 4 °C until further use. 
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2.2.5 In Vitro Characterization 
2.2.5.1 Physicochemical Characterization 
2.2.5.1.1 Aptamer Coupling 
Fluorescence of Cyn 5 labeled Apt was quantified in all colloidal systems to assess the 
binding of Apt. For this, freshly prepared surface-modified particles were washed and 
fluorescence of the supernatant and the pellet was quantified using a Fluostar Optima plate 
reader (BMG Labtech, Offenburg, Germany) at λex 630 nm and λem 670 nm as follows; 




2.2.5.1.2 FTIR Spectroscopy 
The assessment of coupling of Apt with PLGA matrices by Fourier transform infrared 
spectroscopy (FTIR) was done by single reflection diamond ATR module FTIR (Alpha-P, 
Bruker Instruments, Massachusetts, USA). Freeze dried particles were loaded onto ATR 
platinum diamond crystal. Back correction was done in the absence of any sample. The 
average of 21 scans at spectral resolution of 2 cm-1 was taken automatically to obtain each 
spectrum. The spectrum was collected at a range between 4,000 cm-1 and 400 cm−1 and was 
expressed as % transmittance.   
2.2.5.1.3 Elemental Analysis 
PLGA and PVA molecules lack nitrogen in their atomic structure. However, the Apt contains 
nitrogen as a part of nucleotide bases. This fact was used to analyze the presence or absence 
of Apt in formulations by elemental analysis. Freeze dried samples were taken in aluminum 
crucibles, weighed and loaded into the elemental analyzer combustion chamber (VarioMicro 
Cube, Elementar Analysensyteme, GmbH, Langenselbold, Germany). Percentage of carbon, 
hydrogen and nitrogen was obtained and averages of three independent formulations were 
considered. 
2.2.5.1.4 Particle Size and Zeta Potential 
The size distribution of the formulations was measured by dynamic light scattering (DLS) 
using Zetasizer Nano ZS (Malvern Instruments, Malvern, UK). Samples were diluted with 
purified water in a ratio of 1:50 and were analyzed. Before the measurement, the sample 
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temperature was equilibrated to 25 °C. All the measurements were done independently in 
triplicates and the sub runs were adjusted by the instrument automatically. Size distribution 
was evaluated by intensity distribution and PDI was also calculated by Zetasizer Nano ZS 
software. Zeta potential was assessed by laser doppler velocimetry (LDV) using the same 
instrument at conductivity of < 100 μS/cm. All the results were represented as mean ± 
standard deviation of three individual experiments. 
2.2.5.2 Morphological Characterization 
2.2.5.2.1 Atomic Force Microscopy (AFM) 
To study the morphology of the nanoparticles and liposomes, samples were diluted (1:100) 
with purified water and were analyzed using atomic force microscopy (Nano Wizard, JPK 
Instruments, Berlin, Germany). Samples were pipette onto silicon wafers. After 10 min, the 
liquid was aspirated and was let dry for 5 min. After drying, samples were analyzed by 
aluminium coated silicon nitride cantilever (HQ: NSC14AL/BS, Mikromasch, Tallinn, 
Estonia) at a frequency of 148 kHz and a force constant of 5 N/m. Scan speed was adjusted 
between 0.5 and 1.5 Hz. The surface roughness was measured automatically by JPK data 
processing software and was mentioned in the form of root mean square average (RMS Rq) 
values [96-98]. 
2.2.5.2.2 Scanning Electron Microscopy (SEM) 
Hitachi S-510 scanning electron microscope (Hitachi-High Technologies Europe GmbH, 
Krefeld, Germany) was used for the analysis of the morphology of microparticles. Briefly, 20 
µl samples were applied onto specimen stubs with conductive carbon tabs (PLANO Leit-
Tabs; Ø 9 mm) and left to dry under a laminar airflow hood (Labgard Class II, NuAire Inc, 
Plymouth, USA). The samples were then sputtered with gold at 13.3 Pa Argon using an 
Edwards S150 sputter coater (Edwards Vacuum, Crawley, UK) and were examined using 
SEM at an accelerating voltage of 5 kV and focal distance 12 mm under 5.3 × 10−4 Pa 
vacuum [99]. The signals were processed digitally by DISS 5 digital image acquisition 
system (Point Electronic GmbH, Halle, Germany).   
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2.2.5.3 Cell Culture Studies 
2.2.5.3.1 2D Cell Viability and IC50 
Cell viability and IC50 values were evaluatedusing3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. 10,000 MDA-MB-231 cells/well (0.35 cm2) were 
seeded in a 96-well plate and were incubated for 24 h. The cells were then treated with 
different concentrations of SFB-loaded formulations. After 5 h of incubation, the medium 
was removed and replaced with fresh medium and incubated further. After 12 h, the medium 
was removed and replaced with 2 mg/ml MTT reagent containing medium and incubated for 
4 h. The resultant formazan crystals were dissolved using DMSO and absorbance was 
measured in a FluoStar Optima plate reader at 570 nm. The experiment was repeated three 
times and the percentage cell viability was calculated. IC50 values were calculated by the 
concentration of nano/microparticles showing 50 % of the cell survival.  
2.2.5.3.2 3D Cell Viability Assay 
MDA-MB-231 cells were grown on 0.5 % agarose coated 96 well plates at concentration of 
1,500 cells per well. After 72 h, culture was washed three times with PBS (pH 7.4).  Formed 
3D cell cultures were treated with different liposomal formulations for 24 h. The untreated 
cultures were used as control. The morphology and size of 3D cell cultures were then 
visualized under an inverted microscope (CKX53, Olympus, Tokyo, Japan) and percent 
change in area of 3D culture was calculated by following equation; 
3𝐷 𝐶𝑢𝑙𝑡𝑢𝑟𝑒 𝐴𝑟𝑒𝑎 (% ) =  
𝐴𝑟𝑒𝑎 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑡ₓ
𝐴𝑟𝑒𝑎 𝑎𝑡 𝑡𝑖𝑚𝑒 𝑡ₒ
∗ 100 
Whereas, to is zero time of experiment and tx is time when area was measured. 
2.2.5.3.3 Internalization Pathway 
MDA-MB-231 cells were seeded into 96 well plates in a similar manner as for the viability 
experiments. After 24 h, the cells were incubated with either filipin III (6 µg/ml) or 
chlorpromazine (6 µg/ml) for 2 h. Cells were then treated with different formulations. After  
4 h of incubation, the medium was removed and replaced with fresh medium. The cells were 
subsequently incubated for 12 h and the cell viability was determined by MTT assay as 
described above.  
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2.2.5.3.4 Apoptosis Assay 
MDA-MB-231 cells were cultured on sterile cover slips in 24 well plates at a seeding density 
of 50,000 cells per well (1.8 cm2) for 24 h. Cells were washed thrice with cold PBS buffer 
(pH 7.4). 500 µl of different formulations were added to the wells. After 12 h, cells were 
washed again with PBS and fixed using 4 % paraformaldehyde for 15 min. Cells were 
counterstained using DAPI (0.1 µg/ml) solution for 20 min. Washing was performed with 
PBS and cells were examined using a fluorescence microscope (CKX53, Olympus, Tokyo, 
Japan). 
2.2.5.3.5 Reactive Oxygen Species Assessment 
Determination of ROS production was done using 2',7'-dichlorodihydrofluorescein diacetate 
(carboxy-H2DCFDA) conversion into 2’,7’-dichlorofluorescein (DCF) as previously reported 
[100]. Briefly, MDA-MB-231 cells grown in 96 well plates for 24 h were washed (PBS 
buffer; pH 7.4) and incubated with phenol red-free medium containing 25 µM of carboxy-
H2DCFDA for 45 min. The cells were subsequently washed twice with PBS. Cells were then 
treated with nano/microparticles containing 1.0 µM and 1.5 µM of SFB. After 1 h, cells were 
washed again with PBS and lysed using lysis reagent (Promega, Mannheim, Germany). The 
fluorescence was observed at λex 485 nm/ λem 520 nm using a FluoStar Optima plate reader. 
2.2.5.3.6 Metastatic Progression 
Inhibition of cell migration and metastasis was evaluated by wound healing assay. MDA-
MB-231 cells were seeded in 24 well plate. After 24 h, cells were treated with 
nano/microparticles containing 5 µM SFB for 2 h in serum-free medium. A scratch was made 
with a 200 µl pipette tip. Cells were then washed twice with ice-cold PBS (pH 7.4) and fresh 
medium was added. Wound closure was observed using an inverted microscope (CKX53, 
Olympus, Tokyo, Japan) at different time intervals. Cell migration and percentage wound 
healing were also calculated using SketchAndCalcTM® along with Gimp2.10.10® application 
software measuring the distance between wound closures. 
2.2.5.3.7 Cellular Uptake 
For cellular uptake studies, MDA-MB-231 cells were cultured on sterile cover slips in 12-
well plates at a seeding density of 90,000 cells per well (3.5 cm2). After 24 h, the supernatant 
was removed and washed three times with PBS (pH 7.4). Cells were incubated for either 30 
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min or 2 h with different formulations. After washing with PBS cells were fixed with 4% 
paraformaldehyde for 20 min. Cell nucleus was then counterstained with DAPI (0.1 µg/ml) 
for 15 min in the dark. Cells were washed and the cover slips were mounted on to glass slides 
and with FluorSave (Calbiochem Corp, La Jolla, USA). Uptake analysis was performed using 
a confocal laser scanning microscope (LSM700, Carl Zeiss, Jena, Germany). 
2.2.5.4 Chorioallantoic Membrane (CAM) Assay 
Specific pathogen free fertilized eggs were purchased from Mastkukenbruterei Bromann 
(Rheda Wiendenbruck, Germany). The eggs were disinfected with 70 % ethanol and 
incubated in an egg hatching incubator, equipped with an automatic rotator at a temperature 
of 37 °C with a relative humidity of 60 %. On the egg development day 4, hole of 30 mm 
diameter was made into eggshell using a pneumatic egg punch (Schuett Biotech, Germany), 
to expose the CAM surface. The exposed part of the egg was then covered with a small petri 
dish and placed back into the incubator. On the egg development day (EDD) 11, 50 µl of 
different formulations were injected into the mesoderm of CAM, with the help of glass 
cannulas. The eggs were further incubated for 24 h and 1 cm of the CAM was dissected and 
placed on clear glass slide after washing with 0.9 % NaCl. Uptake analysis was performed 
using a confocal laser scanning microscope (LSM700, Carl Zeiss, Jena, Germany). 
2.2.5.5 Hemocompatibility Studies 
2.2.5.5.1 Ex vivo Hemolysis Assay 
To determine the compatibility of the formulations with blood, human erythrocytes were 
isolated from fresh blood as described previously [101]. Briefly, erythrocytes were obtained 
by centrifugation of fresh blood in tubes containing EDTA. The pellet was washed three 
times with PBS buffer (pH 7.4) and diluted to1:50 with PBS. The erythrocytes were 
incubated together with the formulations in v-bottom microtitre plates (1 h, 37°C) and placed 
in an orbital shaker. The plates were centrifuged and the absorbance of the collected 
supernatant was determined at 540 nm in a FluoStar Optima plate reader. As controls, saline 
(NaCl 0.9 %), 1% Triton X-100 and blood were used. 
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2.2.6 In Vivo Characterization 
2.2.6.1 Acute Toxicity Assessment 
Female BALB/c (8–10 weeks old) mice weighing 31.1 ± 2.6 g, were divided into 6 groups 
(n = 3) and with free access of food and water (ad libitum). Experimental protocols were 
approved by the GC University animal experiment and ethical committee and were 
performed in collaboration with the in-house facility of My Pets clinic for clinical 
investigations. The animals were kept at 40 % humidity and a temperature of 22 ± 2 °C. 
The dose of the microparticles was equivalent to the 10 mg/kg dose of SFB. The first group 
was treated with MP, second with MP-Apt, third with MPS and fourth with MPS-Apt. One 
group was administered with the aptamer. Normalsalinetreated group was considered as 
control. The particle suspension was injected in the peritoneal cavity using a 26 G syringe 
needle in two equally divided doses on day 1and day 3. The mice were kept under 
observation for 7 days for alteration in body weight and visual observations for mortality, 
skin, sleek of fur, urine color, feces, salivation, respiration, eyes and sleep pattern and day-
by-day signs of illness. Onthe 7th day, complete blood analysis was done and mice were 
euthanized for tissue histology studies. The vital organs (heart, liver, kidneys and lungs) 
were removed, carefully washed with normal saline and weighed. The comparison was made 





2.2.6.2 Blood Biochemistry 
Blood was drawn by intra-cardiac injection before euthanizing the mice. The effect of 
administration of microparticles on the biochemical markers of the blood was observed on 
the 7th day. These markers include complete blood count (CBC), liver function test (LFT), 
renal function test (RFT) and total plasma protein.  
2.2.6.3 RBC Aggregation Test 
To determine the compatibility of the formulations with blood, mice erythrocytes were 
incubated with different formulations. Briefly, red blood cells were obtained by 
centrifugation of fresh blood in tubes containing EDTA and then the pellet was washed three 
times with PBS (pH 7.4). The dilution with PBS (pH 7.4) was done at 1:10 
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(microparticle:PBS) ratio. The erythrocytes were incubated with the formulations for 30 min 
at 37 °C. Centrifugation was done at 500 rcf and the pellet washed with PBS. The cell 
suspension was directly observed under a light microscope.  
2.2.6.4 Histopathology 
Heart, liver, kidney and lungs were removed after euthanizing the mice and washed with 
PBS (pH 7.4). These organs were visually inspected for lesions and any abnormality.  The 
organs were placed in 4 % formalin solution for 24 h. Dehydration with gradient ethanol 
and fixation in paraffin wax blocks was done. Sections of 1 µm were cut carefully with a 
rotary microtome (Hunan Kaida Scientific Instruments, China) and were transferred to a glass 
slide. Staining was done with H & E stains and tissues were observed under a microscope 
(Olympus BX51M, Tokyo, Japan) for any sign of toxicity [102]. 
2.2.7 Statistical Analysis 
All experiments were performed in triplicates and the values were presented as mean ± 
standard deviation unless otherwise stated. One way ANOVA was performed to identify 
statistically significant differences between the groups. The probability values < 0.05 were 
considered significant. Statistical differences were denoted as “∗” p < 0.05, “∗∗”p < 0.01 and 
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3.1 POLYMERIC MATRICES 
3.1.1 Preparation of Nanoparticles and Microparticles 
Different sized PLGA base colloidal systems were prepared to evaluate the idea of combing 
drug and aptamer in single formulation. The concentration of PLGA and PVA used for the 
preparation of nano/microparticles by solvent evaporation was optimized in preliminary 
experiments. Several solvents were screened and we found that the particle size was at its 
lowest using ethyl acetate with drug solution in THF:EtOH (4:1). Homogenization along with 
constant stirring and addition of water facilitated the evaporation of organic phase. The 
formed nano/microparticles were then washed and used for further studies discussed in 
following sections. 
3.1.2 Characterization 
3.1.2.1 Physico-chemical Characterization 
3.1.2.1.1 Encapsulation Efficiency and In Vitro Release Profile 
A challenging issue regarding the preparation of nano/microparticles is encapsulation of drug. 
Encapsulation efficiency of SFB in nanoparticles and microparticles was 85.7 ± 2.11 % and 
74.64 ± 5.43 %, respectively. Once incorporated, the amount of SFB released from PNS was 
calculated in percentage and data is shown in Figure 3.1A. It is evident from the results that 
more than 50 % drug was released from PNS within the first  
24 h. The remaining SFB was released subsequently (91.31 ± 8.12 % until 96 h). The initial 
burst release was due to the presence of SFB on the surface of the nanoparticles. The 
subsequent release was due to drug entrapment inside nanoscale formulations. This second 
release phase could be due to the diffusion from the pores of non-degraded PLGA matrix as 
reported previously [103-105]. On the other hand, it is clear from Figure 3.1B that nearly    
70 % SFB was released from MPS with in the first 24 h. This represented the initial burst 
release of drug from the surfaces of microparticles. This second phase of release represented 
the combination of diffusion and erosion process of PLGA polymeric chains in microparticles 
[106-110]. 
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3.1.2.1.2 Aptamer Coupling 
Binding of Apt on the surface of nano/microparticles was evaluated by fluorescence analysis 
of Cyn 5 (Figure 3.2). Fluorescence quantification at λex 630 nm and λem 670 nm confirmed 
the attachment of Cyn 5 labeled Apt to the nanoparticle surface. The results showed that 
73.91 ± 4.01 and 70.65 ± 5.01 percent of Apt was bound on the surface of PN and PNS 
respectively (Figure 3.3A). On the other hand, in the case of microparticles, results showed 
that 68.36 ± 2.69 and 60.75 ± 1.02 % of Apt was present on the surface of MP and MPS 
respectively (Figure 3.3B). 
 
 
Figure 3.2: Nanoparticle pellets during surface modification and purification. 
 
PN                   PN-Apt                  PNS                   PNS-Apt 
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Figure3.3: Fluorescence analysis of cyanine 5-Apt at λex/λem 630/670 nm; (A) Fluorescence 
of surface-modified nanoparticles (PN-Apt), surface-modified SFB-loaded nanoparticles 
(PNS-Apt), nanoparticles (PN) and SFB-loaded nanoparticles (PNS); (B) Fluorescence of 
surface-modified microparticles (MP-Apt), surface-modified SFB-loaded microparticles 
(MPS-Apt), microparticles (MP) and SFB-loaded microparticles (MPS). The fluorescence of 















































Results and Discussion 
Page | 41 
 
3.1.2.1.3 FTIR Spectroscopy 
FITR was used to confirm the presence of SFB and Apt in nano/microparticle formulations. 
PN and MP showed a characteristic peak of carboxylic acid (from PLGA) at 1751 cm−1 and 
1750 cm−1, respectively. The alkene stretching due to SFB was present between 1503 cm−1 
and 1501 cm−1. On the other hand, in the spectra of PN-Apt, PNS-Apt, MP-Apt and MPS-Apt 
conjugated acid stretching between 1703 cm−1 and 1700 cm−1 along with imine peaks 
between 1650 cm−1 and 1648 cm−1 were observed. These results showed the presence of SFB 
in formulations. Moreover, peaks of imine showed the coupling of Apt with PLGA in 
formulations (PN-Apt, PNS-Apt, MP-Apt and MPS-Apt). This confirms the successful 
EDC/NHS surface coupling reaction.  
3.1.2.1.4 Elemental Analysis 
Nucleotide bases of Apt contain nitrogen. Therefore, the assessment of presence of Apt can 
also be done by elemental analysis, by which percentages of carbon, hydrogen and nitrogen 
were calculated. PNS showed 0.25 ± 0.06 % nitrogen due to presence of SFB as compared to 
0 % in case of PN. On the other hand, PN-Apt and PNS-Apt showed 1.16 ± 0.45 % and 0.51 
± 0.25 % nitrogen content (with respect to carbon and hydrogen percentages), respectively. 
This confirmed the results obtained from the FTIR analysis.  
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Figure 3.4: FTIR spectrogram of nanoparticles (PN), SFB-loaded nanoparticles (PNS), 
surface-modified nanoparticles (PN-Apt), surface-modified SFB-loaded nanoparticles (PNS-
Apt), microparticles (MP), SFB-loaded microparticles (MPS), surface-modified 
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3.1.2.1.5 Particle Size and Zeta Potential 
Dynamic ligh scattering (DLS) and laser doppler velocimetry (LDV) were used to measure 
particle size and zeta potential. The particle diameter (hydrodynamic diameter as a function 
of intensity) measured by DLS showed an increase with the addition of drug and aptamer 
(Table 3.1). On the other hand, the zeta potential measured was negative in all cases with a 
maximum of -25.29 ± 1.90 for MP-Apt. Hydrodynamic diameter and zeta potential are 
influenced by pH and ionic concentrations. Therefore, the presence of SFB changed the 
diameter and zeta potential of formulations [111-113]. On the other hand, the amide bond 
formed between the carboxylic group of PLGA and the amine of aptamer resulted in the 
attachment of aptamer onto the surface of particles (as shown by FTIR results). This is 
evident from the change in diameter and zeta potential. 
 
Table 3.1: Size and zeta potential of nanoparticles, microparticles and liposomes. 
Formulations Size ± SD (nm) 
Zeta Potential 
± SD (mV) 
PDI 
PN 179.69 ± 5.90 -16.20 ± 0.71 0.19 ± 0.02 
PN-Apt 204.91 ± 12.53 -18.81 ± 1.81 0.24 ± 0.03 
PNS 185.12 ± 10.34 -14.04 ± 0.57 0.21 ± 0.05 
PNS-Apt 222.29 ± 9.91 -16.75± 2.55 0.22 ± 0.07 
MP 692.32 ± 41.38 -21.48± 0.62 0.30 ± 0.01 
MP-Apt 800.07 ± 78.48 -25.29± 1.90 0.32 ± 0.03 
MPS 913.54 ± 45.33 -19.31± 2.20 0.31 ± 0.02 
MPS-Apt 1042.62 ± 52.60 -24.09± 1.47 0.34 ± 0.04 
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Figure 3.5: Size histogram from dynamic light scattering of nanoparticles (PN), surface-
modified nanoparticles (PN-Apt), SFB-loaded nanoparticles (PNS), surface-modified SFB-
loaded nanoparticles (PNS-Apt),microparticles (MP), surface-modified microparticles (MP-
Apt), SFB-loaded microparticles (MPS) and surface-modified SFB-loaded microparticles 
(MPS-Apt). 
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3.1.2.2 Morphological Characterization 
Atomic force and scanning electron microscopies were used to assess the morphology and 
surface roughness of nanoparticles and microparticles. 
3.1.2.2.1 Atomic Force Microscopy (AFM) 
Morphological characterization of nanoparticles was done using an atomic force microscope 
(AFM). AFM analysis revealed spherical shaped particles among all formulations (Figure 
3.6). The coupling of Apt resulted in an increase in the diameter and size distribution of the 
modified particles. Surface roughness (by RMS; Rq) of the nanoparticles was also calculated 
with 38.0 ± 14.8 nm, 54.8 ± 7.1 nm, 47.7 ± 10.9 nm and 64.0 ± 6.0 nm  in case of PN, PN-
Apt, PNS and PNS-Apt. This increase in Rq value represented surface modification in case of 
PN-Apt. More the surface roughness more will be the wettability of the nanoparticles and 
thus will affect nanoparticle-cell interaction [97-98, 114-115].   
3.1.2.2.2   Scanning Electron Microscopy (SEM) 
Morphological characterization of microparticles was done by scanning electron microscopy. 
Samples were dried under laminar airflow hood (Labgard Class II, NuAire Inc, Plymouth, 
USA) on conductive carbon tabs. This resulted in the settlement of microparticles while at the 
same time maintaining their structure. SEM analysis revealed a smooth surface with a diverse 
range of sizes was seen in the micrographs (Figure 3.7). The sizes were between 0.5 to 0.7 
µm, which were smaller than that measured by DLS. This was due to the presence of an 
electrical double layer on the surface of microparticles when measured in suspension form by 
DLS, whereas for SEM, the particles are measured in vacuum. 
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Figure 3.6: AFM images (height) of nanoparticles with surface roughness Rq of 
nanoparticles (PN), surface-modified nanoparticles (PN-Apt), SFB-loaded nanoparticles 
(PNS) and surface-modified SFB-loaded nanoparticles (PNS-Apt). 
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Figure 3.7: SEM micrographs of microparticles (MP) and surface-modified microparticles 
(MP-Apt). Images on the right side depict the size histogram (dynamic light scattering) of the 
nanoparticles. 
3.1.3 In Vitro Evaluation  
3.1.3.1 Cell Culture Studies 
3.1.3.1.1 Cell Proliferation and IC50 
MTT assay was performed to assess the cell viability. Cell viability was dose-dependent, 
increasing with decreasing the nano/microparticle concentration. Maximum viability for 
PNS-Apt and MPS-Apt was achieved with 0.19 µM SFB. IC50 values were 1.75 µM and 1.0 
µM for PNS-Apt and MPS-Apt, respectively. In case of formulations without SFB, an 
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equivalent nano/microparticle amount was considered.PN/MP showed a cell viability of more 
than 80 % as shown in Figure 3.8 and Figure 3.9. This depicted the safety of formulations, in 
the absence of Apt or SFB. The presence of Apt along with SFB decreased cell viability 
significantly (p < 0.001). This decrease indicated the interaction between anti-ErbB3-Apt 
modified particles and cells on one hand and anti-proliferation effect of SFB itself on the 
other hand [116-117]. Therefore, this combination of anti-ErbB3-Apt and drug exhibited a 
synergistic effect thereby addressing the problem of resistance towards SFB [118-121].  
 
 
Figure 3.8: Cell viability assay of nanoparticles (PN), surface-modified nanoparticles (PN-
Apt), SFB-loaded nanoparticles (PNS) and surface-modified SFB-loaded nanoparticles (PNS-
Apt). Statistical differences were denoted as “*” p < 0.05, “**” p < 0.01 and “***” p < 0.001. 
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Figure 3.9: Cell viability assay of microparticles (MP), surface-modified microparticles 
(MP-Apt), SFB-loaded microparticles (MPS) and surface-modified SFB-loaded 
microparticles (MPS-Apt). Statistical differences were denoted as “**” p < 0.01 and “***”    
p < 0.001. 
3.1.3.1.2 Internalization Pathway 
To examine the mechanism of nanoparticle internalization into MDA-MD-231 cells, different 
endocytosis pathways were used. Chlorpromazine and Filipin III were used to suppress the 
clathrin and the caveolae mediated endocytosis, respectively. It was evident from the results 
that cells, pre-treated with chlorpromazine, showed increased cell viability as compared to 
control group and Filipin III group (Figure 3.10). Chlorpromazine blocks clathrin dependent 
internalization pathway of receptor tyrosine kinase [85-87]. The presence of chlorpromazine 
resulted in the blockade of nanoparticle internalization. This was evident from the increased 
cell viability in chlorpromazine treated cells. On the other hand, Filipin III blocks caveolae 
mediated endocytosis. A decreased cell viability in its presence further endorsed that the 
clathrin dependent pathway as a possible mechanism of nanoparticle internalization [122-
124]. 
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Figure 3.10: Pathway analysis of nanoparticles (PN), surface-modified nanoparticles (PN-
Apt), SFB-loaded nanoparticles (PNS) and surface-modified SFB-loaded nanoparticles (PNS-
Apt). Each formulation was equivalent to 1.5 µM SFB concentration in nanoparticles. 
3.1.3.1.3 Apoptosis Assay 
The mechanism of killing of the cells was evaluated by DAPI staining. DAPI is a nuclear 
stain, which binds to double-stranded DNA and can detect the chromatin or nuclear 
condensation and helps localize the formation of apoptotic bodies, which result ultimately in 
the death of cells. Cell shrinkage, loss of cell membrane, blebbing and chromatin degradation 
along with nuclear condensations can be observed using this assay [121, 125-126]. More the 
apoptosis denser DAPI staining will be there in the cells. 
The untreated cells did not show any sign of apoptotic body formation. On the other 
hand,cells treated with different formulations showed significant apoptotic body bodies 
formation. PN/MP showed some cells with nuclear condensation. The cells treated with 
nano/microparticles in the presence of SFB showed nuclear condensation. However, the in 
the presence of Apt chromatin degradation was observed. The nuclear blebbing was also 
prominent due to the presence of SFB and Apt (Figure 3.11 and Figure 3.12). The presence of 
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denser DAPI stained cells showed enhanced apoptosis. Therefore, the formation of apoptotic 
bodies was potentiated in the presence of both SFB and Apt, revealing the synergism 
amongst them. Similar results were reported previously, showing enhanced cell death in the 
presence of anti-ErbB3 aptamer and chemotherapeutic agent [120, 127-129]. These results 
were also in good coordination with cell proliferation assay showing decreased toxicity in 
absence of SFB and/or Apt. 
 
Figure 3.11: Apoptosis assay showing nuclear condensation and chromatin fragmentation of 
nanoparticles (PN), surface-modified nanoparticles (PN-Apt), SFB-loaded nanoparticles 
(PNS) and surface-modified SFB-loaded nanoparticles (PNS-Apt). 
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Figure 3.12: Apoptosis assay showing nuclear condensation and chromatin fragmentation of 
microparticles (MP), surface-modified microparticles (MP-Apt), SFB-loaded microparticles 
(MPS) and surface-modified SFB-loaded microparticles (MPS-Apt). 
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3.1.3.1.4 Reactive Oxygen Species Assessment 
Reactive oxygen species (ROS) can convert carboxy-H2DCFDA into DCF. The results 
showed dose-dependent ROS production in the presence of both drug only and drug-aptamer 
formulations (Figure 3.13). It was obvious that due to presence of SFB increased level of 
ROS production was present. However, in the presence of both the SFB and aptamer, ROS 
were significantly higher (p < 0.01 or p < 0.001) as compared to the blank formulation 
(NP/MP). However, the aptamer alone did not significantly induce ROS production. On the 
other hand, in case of SFB only treated cells, a decrease in level of ROS production was 
obvious. 
The release of the SFB inside cells caused the production of ROS due to the production 
NADPH oxidase in mitochondria. This is the proposed mechanism of ROS production in the 
presence of SFB [130]. The presence of anti-ErbB3 Apt caused an increased production of 
ROS in combination with SFB as compared to only SFB containing formulations. However, 
in the presence of only Apt, low amounts of ROS were produced. Therefore, synergism was 
observed between SFB and Apt in the production of ROS. This synergism was also in good 
correlation with cell proliferation and apoptosis assays i.e. presence of Apt potentiates the 
effect of SFB. Nevertheless, this production of ROS controls cell growth and differentiation 
process, increase in production will cause apoptosis of cells, leading to death [131-133]. This 
fact was confirmed by increasing the incubation time of cells with colloidal systems, which 
reduced the production of DCF. The visual inspection of cells with long incubation time 
showed killing of cells and thus less cells per well were present. Therefore, it was postulated 
that, ROS were responsible for cell death in cell viability assay and Apt potentiated killing by 
SFB also in synergistic way. 
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Figure 3.13: ROS assay measuring the production of 2’,7’-dichlorofluorescein (DCF); A) 
nanoparticles (PN), surface-modified nanoparticles (PN-Apt), SFB-loaded nanoparticle 
(PNS) and surface-modified SFB-loaded nanoparticles (PNS-Apt); B) microparticles (MP), 
surface-modified microparticles (MP-Apt), SFB-loaded microparticles (MPS) and surface-
modified SFB-loaded microparticle (MPS-Apt). Tert-butylhydroperoxide (TBHP) was used 
as a positive control. Statistical differences are denoted as “∗” p < 0.05, “∗∗” p < 0.01 and 
“∗∗∗” p < 0.001. 
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3.1.3.1.5 Metastatic Progression 
Cell progression, migration and inhibition of apoptosis are all associated with the progression 
of cancer. ErbB3 is one of the responsible receptor involved in these progressions [134-136]. 
On the other hand, SFB has also been reported to inhibit metastasis [137-138]. Therefore, we 
performed a wound healing assay to assess the inhibition of metastasis. Presence of Apt and 
SFB blocked progression and wound healing significantly as compared to untreated cells up 
to 24 h (p < 0.001). The percentage of wound healing for nanoparticles treated cells was in 
decreasing order i.e. untreated cells>PN>PN-Apt>PNS>PNS-Apt (100 %, 98 %, 95 %, 91 % 
and 89 % respectively). In similar fashion wound healing for microparticles treated cells was 
in decreasing order from untreated cells>MP>MP-Apt>MPS>MPS-Apt (100 %, 96 %, 92 %, 
90 %, and 88 % respectively). However, after 36 h more than 95 % area was covered by the 
cells in all treatment cases. Nevertheless, SFB and Apt blocked wound healing but in the 
presence of only one of these or in the absence of both, cell migration rate was higher. From 
these findings, it was clear that presence of Apt and SFB have a synergistic effect in blocking 
metastatic progression. 
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Figure 3.14: Effect of formulations on cell migration; scratch was applied using 200 µl 
pipette tip; A) wound healing by scratch test; B) time-dependent wound healing under the 
influence of nanoparticles (PN), surface-modified nanoparticles (PN-Apt), SFB-loaded 
PLGA nanoparticles (PNS-Apt) and surface-modified SFB-loaded nanoparticles (PNS-Apt).  
Statistical differences are denoted as “∗∗∗” p < 0.001. 
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Figure 3.15: Effect of formulations on cell migration; scratch was applied using 200 µl 
pipette tip; A) wound healing by scratch test; B) time-dependent wound healing under the 
influence of microparticles (MP), surface-modified microparticles (MP-Apt), SFB-loaded 
microparticles (MPS) and surface-modified SFB-loaded microparticle (MPS-Apt). Statistical 
differences are denoted as “∗∗” p < 0.01 and “∗∗∗” p < 0.001. 
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3.1.3.1.6 Cellular Uptake 
Cyanine 5 was attached to the 5’ end of Apt as a fluorophore. Detection of its fluorescence 
was used to visualize the uptake of the nano/microparticles. Cells were treated for different 
formulations of nanoparticles and microparticles for different time duration. After 30 min of 
the treatment, most of the particles accumulated near the cell membrane. On the other hand, 
upon incubation with the particles for 2 h, fluorescence was observed mostly near the 
nucleus. This was also confirmed by z-stack images as shown in Figure 3.16-3.18. The 
intensity plot for co-localization shows the intensity of DAPI (cell nucleus) on the x-axis and 
Cyn 5 (aptamer) on the y-axis. Co-localization coefficient was measured by ZEN software 
(Carl Zeiss). This ranges from 0 to 1, where 0indicates no co-localization and 1 indicates 100 
percent co-localization. 
Clathrin dependent internalization and endocytosis was found to be responsible for the 
transfer of nanoparticles from cell membrane to nucleus. ErbB3 receptors are also 
internalized by this mechanism [139-141]. Time dependent locations of PLGA matrices were 
due to this mechanism of transport. Increased cellular toxicity was observed due to binding of 
the particles with these receptors [142]. The z-stack images showed the presence of Cyn 5 
labeled aptamer in nuclear region. Co-localizations were differential, showing co-localization 
coefficients less than 0.4 in case of 30 min incubation time with nanoparticles. This 
represented the location of nanoparticles in cytoplasm away from DAPI channel (nucleus). 
However, for 2 h treatment time, co-localization coefficient was above 0.7 in every treatment 
case, representing nearly the same location of DAPI and Cyn 5, suggesting that the 
nano/microparticles were closer to the nucleus. Based on these findings, Apt modified PLGA 
colloidal systems may be used as a carrier for targeted drug delivery to the cytoplasm of cells 
rich in ErbB3 receptors. The surface modification of different formulations resulted in uptake 
of these formulations, regardless of size. Therefore, the surface modification of particles with 
aptamer can be used for the targeted drug delivery. The presence of a drug together with 





Results and Discussion 




Figure 3.16: Cellular uptake of Cyn 5 labeled nanoparticles after 30 min in MDA-MB-231 
cells; A) cellular uptake, merge images are represented in the form of z-stack to visualize the 
presence of aptamer functionalized nanoparticles near nucleus; B) co-localization of surface-
modified nanoparticles (PN-Apt), surface-modified SFB-loaded nanoparticles (PNS-Apt) and 
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Figure 3.17: Cellular uptake of Cyn 5 labeled nanoparticles after 2 h in MDA-MB-231 cells; 
A) cellular uptake; merge images are represented in the form of z-stack to visualize the 
presence of aptamer functionalized nanoparticles near nucleus; B) co-localization of surface-
modified nanoparticles (PN-Apt), surface-modified SFB-loaded nanoparticles (PNS-Apt) and 
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Figure 3.18: Cellular uptake of Cyn 5 labeled microparticles after 2 h in MDA-MB-231 
cells; A) cellular uptake; merge images are represented in the form of z-stack to visualize the 
presence of aptamer functionalized microparticles near nucleus; B) co-localization of surface-
modified microparticles (MP-Apt), surface-modified SFB-loaded microparticles (MPS-Apt) 
and aptamer (Apt) treated cells. 
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3.1.3.2 Hemocompatibility Studies 
3.1.3.2.1 Ex vivo Hemolysis Assay 
Compatibility of formulations with erythrocytes was evaluated by hemolysis assay. This 
assay determines the release of hemoglobin from erythrocytes after exposure to nanoparticles. 
Percentage of oxyhemoglobin formed after the reaction of released hemoglobin with 
atomospheric oxygen can be determined spectroscopically. Hemolytic potential among all 
formulations was less than 15 % indicating a good hemocompatibility profile (Figure 3.19). 
Maximum hemolysis of 13.01 ± 2.15 % was observed in case of pure drug. From the results, 
it can be concluded that the presence of Apt and SFB did not affect the normal physiology of 
erythrocytes, thereby rendering the formulations suitable for i.v. administration. 
 
Figure 3.19: Hemolysis assay of nanoparticles (PN), surface-modified nanoparticles (PN-
Apt), SFB-loaded nanoparticles (PNS) and surface-modified SFB-loaded nanoparticles (PNS-
Apt). 1% Triton-X 100, 0.9 % NaCl and blood were used as controls. 
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3.1.4 In Vivo Evaluation 
3.1.4.1 Acute Toxicity 
Female BALB/c mice were injected (intra-peritoneal) with different formulations of 
microparticles; aptamer and normal saline were used as controls. Mice were observed for 
7days after injection for any abnormal behavior, skin, sleek of fur, urine color, feces, 
salivation, respiration, eyes and sleep patterns. All the mice survived and showed no 
physical or behavioral changes. A record of body weight was performed to calculate 
percentage change on day 7. All these parameters remained unchanged in all cases, except 
for MPS treated group. The body weight on day 7 in MPS treated group decreased by 3.30 
%. In all other groups, there was an increase in the body weight from nearly 3 to 8 % 
confirming the safety of the formulations (Table 3.2A). The second assessment was the 
effect of formulations on body viscera. The presence of SFB and Apt produced pronounced 
effect on the visceral index (Table 3.2B). There was little increase in visceral indices of 
heart and liver in case of the aptamer, MP-Apt and MPS-Apt groups.   
The effect of microparticles on the blood profiles of the mice was also investigated (Table 
3.2C). There were major differences in the values of total leukocyte count (p < 0.001). 
Hemoglobin concentrations also changed, but only slightly with significantly lower levels in 
case of MPS-Apt (p < 0.001) and MPS (p < 0.001).  However, in the case of the aptamer 
change was less significant (p < 0.05) indicating a less pronounced effect on hemoglobin. 
These results showed that the formulations altered the normal physiological values of mice 
used in the study. As reported previously, the presence of anti-ErbB3 agents (aptamer in our 
case) altered the immune response and was responsible for decreased TLC levels, causing a 
decrease in the inflammatory response [143-144]. This surface functionalized therapy can be 
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Table 3.2A: Body weight changes in mice in different treatment groups. 
Treatments 
Body Wt. Start 
(gm ± SD) 
Body Wt.  End 
(gm ± SD) 
Change (%) 
MP 34.13 ± 1.54 35.07 ± 1.77 2.66 
MP-Apt 30.43 ± 1.18 32.43 ± 2.59 6.17 
MPS 32.30 ± 4.90 31.27 ± 4.82 -3.30 
MPS-Apt 27.01 ± 1.27 30.57 ± 3.00 8.51 
Apt 28.54 ± 2.82 30.10 ± 3.64 5.17 
Control 33.47 ± 2.49 34.60 ± 1.61 3.28 
 
Table3.2B: Body Viscera Index of mice after treatment with formulations. 
Treatments 
Weight (%) ± SD 
Heart Liver Kidney Lungs 
MP 0.49 ± 0.04 4.94 ± 0.27 0.72 ± 0.06 0.78 ± 0.04 
MP-Apt 0.61 ± 0.02 6.41 ± 0.57 0.80 ± 0.01 0.79 ± 0.05 
MPS 0.49 ± 0.04 6.21 ± 0.33 0.71 ± 0.05 1.14 ± 0.06 
MPS-Apt 0.63 ± 0.02 7.09 ± 0.03 0.77 ± 0.01 0.97 ± 0.02 
Apt 0.64 ± 0.05 5.87 ± 0.46 0.73 ± 0.03 0.70 ± 0.03 
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MCV(fl) MCH (pg) MCHC (%) 
Platelets 
(*109/l) 
MP 12.20 ± 0.10 9.60 ± 0.50 6.99 ± 0.03 43.60 ± 0.53 54.27 ± 0.38 15.27 ± 0.06 28.33 ± 0.58 652.00 ± 2.08 
MP-Apt 11.27 ± 0.15 7.27 ± 0.12 5.55 ±0.04 42.00 ± 0.10 62.23 ± 0.12 17.50 ± 0.10 28.23 ± 0.06 1015.33 ± 5.51 
MPS 11.27 ± 0.21 7.20 ± 0.10 5.60 ± 0.03 39.91 ± 0.10 49.60 ± 0.10 14.67 ± 0.06 29.73 ± 0.06 910.67 ± 0.58 
MPS-Apt 11.90 ± 0.10 5.70 ± 0.10 5.98 ± 0.03 42.50 ± 0.20 63.60 ± 4.59 16.80 ± 0.26 28.33 ± 0.21 1167.00 ± 5.69 
Apt 12.33 ± 0.21 6.53 ± 0.06 6.99 ± 0.01 43.13 ± 0.32 62.27 ± 0.15 17.93 ± 0.06 28.80 ± 0.10 959.00 ± 9.85 
Control 12.83 ± 0.31 9.67 ± 0.85 6.07 ± 0.29 44.23 ± 0.61 49.93 ± 1.17 13.90 ± 0.53 26.07 ±0.85 1274.00 ± 20.66 
 
Total leukocyte count (TLC) 
Red blood cells (RBC) 
Hematocrit (HCT) 
Mean corpuscular volume (MCV) 
Mean corpuscular hemoglobin (MCH) 
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3.1.4.2 Blood Biochemistry 
The effects of different formulation on the blood clinical markers i.e. liver function test and 
kidney function test were investigated (Figure 3.20 and Figure 3.21). Nearly in all the 
treatment groups, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 
increased significantly (p < 0.001). Exceptions were in case of MP (ALT) and MP-Apt 
(AST), where no profound change was observed. However, a profound decrease in levels of 
alkaline phosphatise (ALP) was found in all treatment groups, except MP-Apt. These 
elevated levels after treatment were representative of cardiac problems and non-alcoholic 
fatty liver. Moreover, AST to ALT ratio was more than 3 which was indicative of liver 
inflammation, fatty liver and cardiac injury. These results were in accordance with the results 
of body visceral indices. A decrease in total serum proteins and a slight increase in bilirubin 
also predicted liver malfunctioning, usually associated with fatty liver [145-146]. Kidney 
function tests (Figure 3.22) included uric acid, creatinineand blood urea nitrogen (BUN). The 
values changed significantly (p < 0.01 or p < 0.001) in all cases, except MP-Apt in the case of 
uric acid. The concentrations of these markers indicated the poor kidney function or 
malfunctioning of the liver [146]. Liver and heart muscles are usually rich in ErbB3 
receptors. Therefore, the attachment of aptamer on the surface of microparticles mediated 
their delivery to the organs rich in ErbB3 receptors, resulting in a change in the normal 
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Figure 3.20: Liver function test of microparticles (MP), surface-modified microparticles 
(MP-Apt), SFB-loaded microparticles (MPS) and surface-modified SFB-loaded 
microparticles (MPS-Apt). Statistical differences are denoted as “∗∗” p < 0.01 and “∗∗∗” p < 
0.001 and were calculated using controls in each case. 
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Figure 3.21: Kidney function test of microparticles (MP), surface-modified microparticles 
(MP-Apt), SFB-loaded microparticles (MPS) and surface-modified SFB-loaded 
microparticles (MPS-Apt). Statistical differences are denoted as “∗∗” p < 0.01 and “∗∗∗” p < 
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3.1.4.3 RBC Aggregation Test 
RBC aggregation test was performed to monitor the effect of formulations on RBC. The 
presence of aptamer and SB showed minor structural and morphological changes in RBCs 
(Figure 3.22). These results were in accordance with the ROS assay. ROS dependent RBCs 
damage is one of the well-known mechanisms. Therefore, the potentiated effect was observed 
in the presence of both SFB and Apt. However, the damage was not too much extent to 
damage complete RBC morphology and results were comparable with the CBC profile. CBC 
profile showed a small decrease in RBC count but it was in normal profile range. On the 
other hand, hematocrit values were in the normal range of 39.70-71.80 % [147-148]. 
Therefore, this functionalized advance colloidal system can be used for targeted 
chemotherapy.  
3.1.4.4 Histopathology 
The histopathological investigation was done for heart, liver, kidney and lung. It was obvious 
from the results that mild to moderate toxicity was seen in case of heart muscles. Necrosis, 
infiltration of leukocyte, mild granulative tissue and collagen accumulation were observed in 
the case of aptamer and formulations containing either both SFB and Apt or alone. These 
results were in accordance with the body visceral index and plasma profile as heart weight 
increased in these cases as compared to the control group. Liver showed signs of fibrosis, 
pyknosis (condensation of nuclei due to apoptosis) and micro and macrovesicular fatty 
changes. The anisokaryosis (larger nuclei) and binucleated hepatocytes suggested 
regenerative responses as well as the fatty degeneration mostly in case of MP-Apt and 
MPS-Apt [149]. Some brown necrotic bodies were also visible. Kidneys did not show any 
major changes in any of the treatment groups. These findings demonstrated the presence of 
mild nephritis. On the other hand, no major change in lung histology was also obvious. 
Normal alveolar structures were observed and arterioles were also normal. These 
investigations reported the safety of this surface functionalized system.  
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Figure 3.22: RBC aggregation test of microparticles (MP), surface-modified microparticles 
(MP-Apt), SFB-loaded microparticles (MPS), surface-modified SFB-loaded microparticles 
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Figure 3.23: Effect of different formulations on histology of heart tissues; H & E staining of 
microparticles (MP), surface-modified microparticles (MP-Apt), SFB-loaded microparticles 
(MPS), surface-modified SFB-loaded microparticles (MPS-Apt) and aptamer (Apt). 
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Figure 3.24: Effect of different formulations on histology of liver tissues; H & E staining of 
microparticles (MP), surface-modified microparticles (MP-Apt), SFB-loaded microparticles 
(MPS), surface-modified SFB-loaded microparticles (MPS-Apt) and aptamer (Apt). White 
boxes show anisokaryosis, Red box shows necrotic bodies and the black box shows pyknosis. 
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Figure 3.25: Effect of different formulations on histology of kidney tissues; H & E staining 
of microparticles (MP), surface-modified microparticles (MP-Apt), SFB-loaded 
microparticles (MPS), surface-modified SFB-loaded microparticles (MPS-Apt) and aptamer 
(Apt). 
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Figure 3.26: Effect of different formulations on histology of lung tissues; H & E staining of 
microparticles (MP), surface-modified microparticles (MP-Apt), SFB-loaded microparticles 
(MPS), surface-modified SFB-loaded microparticles (MPS-Apt) and aptamer (Apt). 
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3.2 LIPOSOMES 
3.2.1 Preparation of Liposomes 
The size of liposomes plays an important role in cellular internalization [103]. Therefore, the 
concentrations of DPPC, cholesterol and DSPE-PEG (2000) cyanur used for the preparation 
of empty and SFB-loaded liposomes (LP, LPS respectively) were adjusted to 80:10:10, 
respectively. Sonication of dry lipid film after hydration is thought to be the most effective 
method of MLVs formation. However, sonicated liposomes are not stable to much extent as 
well as their size distribution is high, hence, extrusion was used as post process step [150]. 
Thus colloidal system was extruded 25 times through 200 nm polycarbonate membrane filters 
(Whatman, Buckinghamshire, UK) using an extruder (Avanti Mini, Avanti Polar Lipids Inc., 
Alabaster, USA).  
3.2.2 Characterization 
3.2.2.1 Encapsulation Efficiency and Aptamer Coupling 
A challenging issue regarding the preparation of liposomes is encapsulation of 
chemotherapeutic agent. Therefore, encapsulation efficiency was calculated. Encapsulation 
efficiency of SFB was 64.1 ± 3.3 %. Binding of Apt on the surface of liposomes was 
evaluated by fluorescence analysis of Cyn 5. Fluorescence quantification at λex 630 nm and 
λem 670 nm confirmed the attachment of Cyn 5 labeled Apt to the liposome surface. The 
results showed that 61.79 ± 2.45 and 60.41 ± 3.35 percent of Apt was bound on the surface of 
LP and LPS, respectively. 
3.2.2.2 Physico-chemical Characterization of Liposomes 
3.2.2.2.1 Particle size and zeta potential 
Film hydration method used to prepare liposomes was optimized in preliminary testing for 
the concentration of all ingredients. Hence, results were highly reproducible. Optimized 
formulations were then assessed for hydrodynamic diameter and zeta potential 
measurements. The size distribution (Polydispersity Index; PdI) was found to be under 0.21 ± 
0.02 in case of LP showing nearly monomodel distribution of size.  It was obvious that 
hydrodynamic diameter was increased by incorporating the SFB into liposomes with a slight 
increase in PDI to 0.26 ± 0.01. On the other hand, the presence of Apt also changed the size 
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of the liposomes. Similar increase in diameter, after attachment of Apt on the surfaces, was 
also reported earlier [29, 91]. The incorporation of SFB as well as the presence of Apt also 
influenced the zeta potential. The zeta potential measurements were negative in all cases 
ranging from -21.8 ± 2.5 (LPS-Apt) to -14.0 ± 1.7 for LP (Table 3.3). Therefore, the 
incorporation of SFB as well as the presence of aptamer changed zeta potential also. 
Table 3.3: Size and zeta potential of liposomes. 
Formulations Size ± SD (nm) Zeta Potential 
± SD (mV) 
PDI ± SD 
LP 120.71 ± 5.91 -14.01 ± 1.74 0.21 ± 0.02 
LP-Apt 142.97 ± 12.56 -18.42 ± 1.17 0.25 ± 0.01  
LPS 131.34 ± 9.14 -18.84 ± 1.26 0.26 ± 0.03 
LPS-Apt 155.01 ± 11.92 -21.38± 2.53 0.28 ± 0.02 
 
3.2.2.2.2 Atomic Force Microscopy (AFM) 
Morphological characterization was done using an atomic force microscope (AFM). AFM 
analysis revealed diverse sizes of liposomes (Figure 3.27). The coupling of Apt resulted in an 
increase in the size and size distribution of the modified particles. Surface roughness (by 
RMS; Rq) of the liposomes was also calculated with 2.2 ± 1.2 nm and 5.4 ± 1.1 nm in case of  
LPS and LPS-Apt. This increase in Rq value represented surface modification in case of 
LPS-Apt. More the surface roughness more will be the wettability of the nanoparticles and 
thus will affect nanoparticle-cell interaction [97-98, 114-115].   
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Figure 3.27: AFM images (height) of liposomes with surface roughness Rq; SFB-loaded 
liposomes (LPS) and surface-modified SFB-loaded liposomes (LPS-Apt). 
3.2.2.3 Cell Culture Studies 
3.2.2.3.1 2D Cell Viability and IC50 
The assessment of cell viability in the presence of formulations was done by MTT assay. The 
presence of both SFB and Apt resulted in a decrease in cell viability, with maximum effect at 
highest concentrations (4 µM SFB or equivalent). This response was dose-dependent i.e. 
increasing with decreasing the dose of the liposome and vice versa. Therefore, the lowest 
dose of the formulations (0.25 µM SFB or equivalent) showed a viability of 92.17 ± 3.25 % 
for LPS-Apt and to 94.27 ± 5.91 % in the case of LPS. Inhibitory response was strongest at 
heights concentrations when compared with LP with p < 0.001. IC50 value was 0.75 µM and 
1.25 µM for LPS-Apt and LPS, respectively. Moreover, LP showed nearly more than 80 % 
cell viability even at the highest concentration (Figure 3.28).  This suggested that 
LPS           LPS-Apt 
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formulations are relatively safe in the absence of SFB or Apt. The presence of aptamer in 
formulations showed an increase in the effect of chemotherapeutic agent due to the presence 
of drug on one hand and due to targeted delivery of the formulations in the presence of 
aptamer [116-117]. The combination of SFB and Apt exhibited targeted SFB liposomes 
delivery towards ErbB3 rich cells there by addressing the problem of generalized toxicity due 
to non-specific drug delivery. 
 
Figure 3.28: 2D Cell viability assay of liposomes (LP), surface-modified liposomes (LP-
Apt), SFB-loaded liposomes (LPS) and surface-modified SFB-loaded liposomes (LPS-Apt). 
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3.2.2.3.2 3D Cell Viability 
Effect of different formulations on the size of 3D culture was also investigated. In the case of 
formulations without SFB an equivalent liposome amount was considered. It was evident that 
presence of SFB and/Apt decreased the culture size. After 24 h, culture size was 32.05 ± 
75.97 % of that of original in case of LPS-Apt and 73.71 ± 8.82 % in case of LP [153]. This 
depicted the safety of formulations, in the absence of Apt or SFB. The presence of SFB along 
with Apt decreased cell viability significantly (Figure 3.29). This decrease indicated the 
interaction between anti-ErbB3-Apt modified liposomes and cells on one hand and anti-
proliferative effect of SFB itself on the other hand.  Therefore, this combination of anti-
ErbB3-Apt and drug exhibited a synergistic effect thereby addressing the problem of 
resistance towards SFB [118]. 
3.2.2.3.3 Internalization Pathway 
Clathrin and caveolae-mediated endocytosis pathways were evaluated to examine the 
mechanism of liposome internalization into MDA-MD-231 cell. Chlorpromazine and Filipin 
III were used to suppress the clathrin and the caveolae-mediated endocytosis, respectively. It 
was evident from the results that cells, pre-treated with chlorpromazine/Filipin III, showed 
increased cell viability as compared to control group (Figure 3.30). The presence of 
chlorpromazine and Filipin III resulted in the blockade of liposomal internalization. This was 
evident from the increased cell viability in chlorpromazine or Filipin III treated cells, 
suggesting both clathrin and caveolae-mediated internalization pathways. An increased cell 
viability in their presence endorsed that the dual clathrin and caveolae-mediated dependent 
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Figure 3.39: A) 3D cell culture viability assay of liposomes; B) Change in percentage area of 
3D culture of liposomes (LP), surface-modified liposomes (LP-Apt), SFB-loaded liposomes 
(LPS) and surface-modified SFB-loaded liposomes (LPS-Apt). 
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Figure 3.30: Pathway analysis of liposomes (LP), surface-modified liposomes (LP-Apt), 
SFB-loaded liposomes (LPS) and surface-modified SFB-loaded liposomes (LPS-Apt). Each 
formulation was equivalent to 2 µM SFB concentration in liposomes. 
3.2.2.3.4 Apoptosis Assay 
The mechanism of cells death was evaluated by DAPI staining. DAPI is a nuclear stain, 
which binds to double-stranded DNA. It can be used for the detection of chromatin or nuclear 
condensation and degradation. It can be used to detect the formation of apoptotic bodies 
which result ultimately in the death of cells. When cells were treated with different 
formulations, significant damage and apoptotic bodies formation was observed [125-127]. 
Chromatin fragmentation as well as nuclear condensation was observed in case of cells 
treated with SFB and Apt (Figure 3.31). On the other hand, un-treated cells show no clear 
evidence of apoptotic bodies formation. Therefore, the presence of SFB and Apt were thus 
responsible for the apoptosis leading to cell death. These results were also in good 
coordination with cell viability assay, showing more apoptotic bodies in the presence of both 
SFB and Apt as compared to other formulations. 
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Figure 3.31: Apoptosis assay showing nuclear condensation and chromatin fragmentation of 
liposomes (LP), surface-modified liposomes (LP-Apt), SFB-loaded liposomes (LPS) and 
surface-modified SFB-loaded liposomes (LPS-Apt). 
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3.2.2.3.5 Cellular Uptake 
Cellular uptake was visualized by confocal laser scanning microscopy (CLSM). Cyn 5 was 
attached to 5’ end of the aptamer, which was bound to surface of liposomes. The nucleus of 
the cell incubated with the formulations was stained with DAPI. CLSM images showed the 
presence of surface-modified liposomes within the cells. The red fluorescence of aptamer can 
be seen throughout the cytoplasm, particularly near the nucleus.  
Clathrin-dependent as well as caveolae-mediated internalization (Figure 3.30) was found to 
be responsible for the transfer of liposomes from cell membrane to different cytoplasmic 
regions [154-155]. This might be the possible mechanism for the toxicity of SFB [139-141]. 
These pathways were then responsible for the movement of liposomes through cytoplasm and 
then to nuclear region. The z-stack images also showed the presence of Cyn 5 labeled 
aptamer near the nuclear region (Figure 3.32A). The intensity plot for co-localization shows 
DAPI on the x-axis and Cyn 5 on the y-axis. Co-localization coefficient was measured by 
ZEN software (Carl Zeiss, Jena, Germany). This ranges from 0 to 1, where 0 shows no co-
localization and 1 shows 100 percent co-localization. Co-localization coefficients were 
between 0.4 and 0.7. This explains partial co-localized liposomes in nuclear region. The 
intensity plot depicted the more intense fluorescence of Cyn 5 channel in case of LP-Apt and 
aptamer treated cells. However, in the LPS-Apt treated cells, these channels were almost 
equally co-localized (Figure 3.32B). Aptamer delivered LPS to the nucleus, therefore DAPI 
and Cyn 5 fluorescence was nearly equally co-localized in case of LPS-Apt. Hence, the 
presence of anti-ErbB3 aptamer enhanced the internalization of liposomes by clathrin-
mediated pathway. Therefore, this combination of SFB and anti-ErbB3-aptamer can be used 
to increase the chemotherapeutic effects. This combination, therefore, will not only increase 
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Figure 3.32: Cellular uptake of Cyn 5 labeled liposomes after 2 h in MDA-MB-231 cells; A) 
cellular uptake; merge images are represented in the form of z-stack to visualize the presence 
of aptamer functionalized microparticles near nucleus. B) co-localization of surface-modified 
liposomes (LP-Apt), surface-modified SFB-loaded liposomes (LPS-Apt) and aptamer (Apt) 
treated cells. 
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3.2.2.4 Chorioallantoic Membrane Assay 
The chorioallantoic membrane (CAM) model offers an excellent ethical and cost effective 
alternative to in vivo. Therefore, CAM model was used to mimic the in vivo safety and 
evaluation of liposomal preparations. There are different sort of studies available for CAM 
model including angiogenesis, transfection and tumor growth. Transfecting ability of surface-
modified liposomes was investigated during current study. 
On the EDD 11, 50 µl of different formulations were injected into the mesoderm of CAM. 
No sign of major toxicity or retardation in the embryogenesis was observed for 24 h. CAM 
microvasculature was also intact and showed no injury. Furthermore, after 24 h 1 cm of the 
mesoderm of CAM was dissected and placed on clear glass slide after washing with 0.9 % 
NaCl. Uptake analysis performed using a confocal laser scanning microscope (LSM700, Carl 
Zeiss, Jena, Germany) showed the presence of Cyn 5 labeled liposomes in CAM (Figure 
3.33). Similar results were reported previously [156], showing minimum toxicities of 
formulations and localization of formulations in mesoderm of CAM.  
 
 
Figure 3.33: CLSM micrograph of CAM section showing presence of surface-modified 
liposomes (LP-Apt) and surface-modified SFB-loaded liposomes (LPS-Apt). 
 
LP-Apt     LPS-Apt 
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3.2.2.5 Hemocompatibility Studies 
3.2.2.5.1 Ex vivo Hemolysis Assay 
Compatibility of formulations with erythrocytes was evaluated by hemolysis assay. This 
assay determines the release of hemoglobin from erythrocytes after exposure to liposomes. 
Percentage of oxyhemoglobin formed after the reaction of released hemoglobin with 
atomospheric oxygen can be determined spectroscopically. Hemolytic potential among all 
formulations was less than 15 % indicating a good hemocompatibility profile (Figure 3.34). 
Maximum hemolysis of 12.59 ± 1.91 % was observed in case of pure drug. From the results, 
it can be concluded that the presence of SFB and Apt did not affect the normal physiology of 
erythrocytes, thereby rendering the formulations suitable for i.v. administration. 
 
Figure 3.34: Hemolysis assay of liposomes (LP), surface-modified nanoparticles (LP-Apt), 
SFB-loaded nanoparticles (LPS) and surface-modified SFB-loaded nanoparticles (LPS-Apt). 
1% Triton-X 100, 0.9 % NaCl and blood were used as controls. 
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4.1 SUMMARY AND OUTLOOK 
The current project gave a detailed insight of surface modification of different advance 
colloidal systems along with their in vitro and in vivo targeting capabilities. Three different 
colloidal systems (nanoparticles, microparticles and liposomes) were evaluated for their 
efficacies and consistencies in results. 
The introduction contains an overview for the passive and active targeting of 
chemotherapeutic agents with different colloidal systems. Different methods of preparation 
and characterization of these colloidal systems were reviewed. This formed the root level for 
the use of these formulations in the current project. Furthermore, a brief introduction about 
aptamers and different examples of targeting molecules was also given to elaborate on 
aptamers’ specific nature. This provided the basis of surface modification of colloidal 
formulations with aptamer of interest.  
Sorafenib tosylate (SFB) was selected as a chemotherapeutic agent because it has low 
solubility and low bioavailability. Its LogP value is 4.54 with biopharmaceutical 
classification systems class IV. Systemic toxicity due to non-specific drug delivery is also 
issues with the use of SFB. Another problem associated with the use of this chemotherapeutic 
agent is the development of drug resistance after consecutive administrations. Therefore, the 
current study was designed to improve the efficiency of cancer therapy using sorafenib-
loaded colloidal systems coupled with anti-ErbB3-aptamer (Apt). There first part of result 
and discussion included characterization of SFB-loaded PLGA matrix systems i.e. 
nanoparticles and microparticles. The encapsulation efficiencies revealed the loading of the 
drug inside these carrier systems. The physicochemical investigation by Fourier transform 
infrared spectroscopy, elemental analysis and fluorescence analysis elaborated the success of 
surface modification of these systems with Apt. Furthermore, morphological analysis by 
atomic force and scanning electron microscopy supported these results and showed an 
optimal surface roughness profile for cell surface interactions.  
Cell culture studies showed a positive impact of the combination of SFB and Apt. The 
presence of SFB and Apt together showed maximum cytotoxicities compared to other 
formulations. Dose-dependent toxicities were demonstrated using the cell viability assay. 
Moreover, time-dependent formulation delivery, to the cytoplasm and subsequently to the 
nuclear membrane, was observed by CLSM visualization.  Higher reactive oxygen species 
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production was observed in the presence of both SFB and Apt as compared to blank 
formulations. However, the aptamer alone did not significantly induce ROS production. Upon 
treatment of the cells with different concentration of particles, a significant dose-dependent 
ROS production was noticed. The metastatic inhibition by the particles, especially those with 
SFB and Apt was evident from the scratch test. The absence of both SFB and Apt resulted in 
complete healing of wound within 24 h.  
Ex vivo hemolysis studies demonstrated the hemocompatibility of the PLGA matrices, thus 
mimicking in vivo safety of these formulations. The presence of SFB as well Apt did not 
change the hemolytic potential of formulations to much extent. All the formulations were 
more hemocampatible as compared to pure drug. Moreover, RBC aggregation test showed no 
profound change in the morphology of RBCs. In vivo assessment by the blood profiles along 
with serum biochemistry stamped the safety of the formulation. Nevertheless, heart and liver-
specific toxicities were evident in the presence of SFB and Apt but the overall body visceral 
index was normal.  
Results and discussion also included characterization of SFB-loaded liposomes. The 
physicochemical investigation of the liposomes using dynamic light scattering and laser 
Doppler velocimetry revealed nearly monomodel size range from 121 nm to 155 nm suitable 
for cellular internalization. However, the presence of SFB and Apt influenced the 
hydrodynamic diameters and zeta potentials of formulations. Furthermore, morphological 
characteristics were described by atomic force microscopy and showed optimal sizes and 
surface roughness profile for cell surface interactions.  
Synergistic dose-dependent cytotoxicities were demonstrated using SFB and Apt in 
liposomes in 2D cell culture techniques. The evaluation of toxicity was also visualized in 3D 
cell cultures and revealed a decrease in 3D culture sizes. This effect was also evident in 
apoptosis assay showing nuclear condensation as a possible mechanism of cell death. The 
presence of surface-modified liposomes, inside cells was visualized using CLSM. These 
investigations showed the presence of liposomes inside the cell, especially near the nuclear 
region (co-localization coefficient; 0.4-0.7).  
In order to analyze the in vivo safety as well as the transfection potential of surface modified 
liposomes the chorioallantoic membrane model (CAM) was used. The presence of these 
formulations in the mesoderm of the CAM was visualized by CLSM. No evidence of clear 
toxicity was observed on the development of the embryo. Furthermore, the 
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hemocompatibility studies of liposomes also demonstrated the safety of these formulations 
when compared to pure drug.  
Therefore, the combination of chemotherapeutic agent and aptamer together with colloidal 
drug delivery systems will pave the way to a powerful tool in anticancer therapies. Moreover, 
the presence of aptamer will also solve the problems of side effects of chemotherapeutic 
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4.2 Zusammenfassung und Ausblick 
Die aktuelle Projektarbeit gibt einen detaillierten Einblick in die Oberflächenmodifikation 
verschiedener fortgeschrittener kolloidaler Systeme sowie in deren In-vitro- und In-vivo-
Targeting-Fähigkeiten. Drei verschiedene kolloidale Systeme (Nanopartikel, Mikropartikel 
und Liposomen) wurden auf ihre Wirksamkeit und Konsistenz der Ergebnisse untersucht. 
In der Einleitung wird ein Überblick zum passiven und aktiven Targeting von 
Chemotherapeutika mit unterschiedlichen Kolloidsystemen gegeben. Verschiedene Methoden 
zur Herstellung und Charakterisierung dieser kolloidalen Systeme werden besprochen. Dies 
bildete denAusgangspunkt für die Verwendung dieser Formulierungen im Promotionsprojekt. 
Darüber hinaus wurde eine kurze Einführung über Aptamere und verschiedene Beispiele für 
Targeting-Moleküle gegeben, um die selektiven Bindungseigenschaften der Aptamere zu 
erläutern. Dies lieferte die Grundlage für die Oberflächenmodifizierung kolloidaler 
Formulierungen mit dem interessierenden Aptamer. 
Sorafenib-Tosylat (SFB) wurde als Chemotherapeutikum ausgewählt. Der Grund hierfür war 
die niedrige Löslichkeit und Bioverfügbarkeit mit einem LogP Wert von 4,54 und der 
Biopharmazeutischen Klassifikation von IV. Des Weiteren zeigt SFB aufgrund nicht-
spezifischer Wechselwirkungen eine systemische Toxizität. Ein weiteres Problem, das bei 
Verwendung dieses Chemotherapeutikums entsteht, ist die Entwicklung einer 
Wirkstoffresistenznach mehrmaliger Applikation. Daher sollte die aktuelle Studie die 
Wirksamkeit der Krebstherapie unter Verwendung von mit SFB-beladenen kolloidalen 
Systemen in Kombination mit Anti-ErbB3-Aptamer (Apt) verbessern. Der erste Teil des 
Ergebnisses und der Diskussion umfasste die Charakterisierung von SFB-beladenen PLGA-
Matrixsystemen, d. h. Nanopartikeln und Mikropartikeln. Die Daten zu 
Einkapselungseffizienzen zeigten eine erfolgreiche Beladung der Trägersysteme mit SFB. 
Die physikalisch-chemische Untersuchung mittels Fourier-Transformations-
Infrarotspektroskopie, Elementaranalyse und Fluoreszenzanalyse bestätigte die 
Oberflächenmodifikation dieser Systeme mit Apt. Darüber hinaus stützten morphologische 
Analysen mittels Atomkraft- und Rasterelektronenmikroskopie diese Ergebnisse und zeigten 
ein optimales Oberflächenrauheitsprofil für Zelloberflächenwechselwirkungen. 
Zellkulturstudien verdeutlichten einen positiven Einfluss der Kombination von SFB und Apt. 
Das Vorhandensein von SFB und Apt zusammen zeigte maximale Zytotoxizitäten im 
  Summary and Outlook 
 
Page | 92 
 
Vergleich zu anderen Formulierungen. Dosisabhängige Toxizitäten wurden unter 
Verwendung des Zelllebensfähigkeitstests nachgewiesen. Darüber hinaus ist die 
zeitabhängige Abgabe der Formulierung an das Zytoplasma und anschließend an die 
Kernmembran mit Hilfe der CLSM-Visualisierung beobachtet worden. In Gegenwart von 
SFB und Apt konnte im Vergleich zu Kontrollpräparaten eine höhere Produktion reaktiver 
Sauerstoffspezies beobachtet werden. Das Aptamer allein induzierte jedoch keine signifikante 
ROS-Produktion. Bei Behandlung der Zellen mit unterschiedlicher Partikelkonzentration 
wurde eine signifikante dosisabhängige ROS-Produktion festgestellt. Die metastatische 
Hemmung durch die Partikel, insbesondere die mit SFB und Apt, wurde aus dem Kratztest 
ersichtlich. Das Fehlen von SFB und Apt führte zu einer vollständigen Wundheilung 
innerhalb von 24 Std. 
Ex-vivo-Hämolysestudien zeigten die Hämokompatibilität der PLGA-Matrices und 
verdeutlichten die In-vivo-Sicherheit dieser Formulierungen. Das Vorhandensein von SFB 
sowie Apt änderte das hämolytische Potential der Formulierungen nicht wesentlich. Alle 
Formulierungen weisen eine höhere Hämokompatibiltät im Vergleich zu SFB auf. Der RBC-
Aggregationstest wies  keinemorphologische Veränderung von RBCs auf. Die In-vivo-
Auswertung der Blutprofile sowie die Serumbiochemie bestätigten die Sicherheit der 
Formulierung. Trotzdem kam es in Gegenwart von SFB und Apt zu herz- und 
leberspezifischen Toxizitäten, jedoch war der viszerale Index des gesamten Körpers normal. 
Ergebnisse und Diskussion umfassten die Charakterisierung von SFB-beladenen Liposomen. 
Die physikalisch-chemische Untersuchung der Liposomen mittels dynamischer Lichtstreuung 
und Laser-Doppler-Velocimetrie ergab eine nahezu monomodalen Größenverteilung von  
121 nm bis 155 nm, der für die Internalisierung von Zellen geeignet ist. Das Vorhandensein 
von SFB und Apt beeinflusste jedoch die hydrodynamischen Durchmesser und Zeta-
Potentiale der Formulierungen. Darüber hinaus wurden morphologische Eigenschaften durch 
Rasterkraftmikroskopie untersucht und zeigten optimale Größen und 
Oberflächenrauheitsprofile für Zelloberflächenwechselwirkungen. 
Synergistische dosisabhängige Zytotoxizitäten wurden unter Verwendung von SFB und Apt 
in Liposomen in 2D-Zellkulturtechniken gezeigt. Die Bewertung der Toxizität wurde auch in 
3D-Zellkulturen durchgeführt und resultierte in einer Flächenverkleinerung der 3D Kulturen. 
Dieser Effekt wurde auch im Apoptose-Assay deutlich, der die Kernkondensation als 
möglichen Mechanismus für den Zelltod zeigte. Das Vorhandensein von 
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oberflächenmodifizierten Liposomen in Zellen ist unter Verwendung von CLSM sichtbar 
gemacht worden. Diese Untersuchungen zeigten das Vorhandensein von Liposomen in der 
Zelle, insbesondere in der Nähe der Kernregion (Co-Lokalisierungskoeffizient; 0,4-0,7). 
Zur Bestimmung der In-vivo-Sicherheit sowie des Transfektionspotentials von 
oberflächenmodifizierten Liposomen wurde das Chorioallantoismembranmodell (CAM) 
herangezogen.   CLSM Studien zeigten das Vorhandensein der Formulierungen im 
Mesoderm des CAM und esgab keine Hinweise auf eine Toxizität während der 
Embryonalentwicklung. Studien bezüglich der Hämokompatibilität der Formulierungen 
bestätigten die Sicherheit im Vergleich zuSFB. 
Zusammenfassend lässt sich sagen, dass eine kolloidale Formulierung bestehend aus einer 
Kombination von Chemotherapeutikum und Aptamerein leistungsstarkes Medikament in der 
Krebstherapie darstellt. Durch die Anwesenheit von Aptamer wird ebenso das 
Nebenwirkungspotential erheblich reduziert, da sich die Formulierungen spezifisch bei 
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